Stockwinners Market Radar for September 07, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:07 EDT Ares Management co-founder Kaplan sells $20.7M in common stock - In a regulatory filing, Ares Management disclosed that its co-founder David Kaplan sold 200K shares of common stock on September 5th in a total transaction size of $20.7M.

20:18 EDT Cathie Wood's ARK Investment bought 337.8K shares of PacBio today

20:14 EDT Cathie Wood's ARK Investment sold 13.5K shares of Nvidia today

18:56 EDT 3D Systems comments on ongoing partnership with Align Technology - 3D Systems (DDD) issued a statement on the company's ongoing partnership with Align Technology (ALGN in response to shareholder inquiries related to Align's recent announcement that it has entered into a definitive agreement to acquire privately held Cubicure Gmbh: "3D Systems' 25-year partnership with Align where 3D Systems provides hardware, materials, processing, and services for Align in connection with its highly efficient indirect production of aligners remains strong. Align operates hundreds of 3D Systems' printers producing over one million parts daily and continues to rely on 3D Systems to support its operations. 3D Systems' forecasts remain intact and already account for Align's existing partnership with Cubicure". Cubicure's R&D efforts on direct 3D printing of aligners have had no impact on 3D Systems. 3D Systems continues to move forward with advanced R&D to further its capabilities for direct printing aligners as that approach is further evaluated as a complement to indirect production.

18:30 EDT IX Acquisition announces extension to complete business combination - IX Acquisition "announced that its board of directors has decided to extend the date by which the Company must consummate an initial business combination from September 12, 2023 for an additional month, to October 12, 2023. This is the sixth of twelve potential one-month extensions of the Deadline Date available to the Company pursuant to its Amended and Restated Memorandum and Articles of Association. The Company further announced that on or before September 12, 2023, IX Acquisition Sponsor LLC will deposit $160,000 into the Company's trust account in connection with this extension."

18:27 EDT Permian Resources CAO Jensen sells 171,817 class A shares - In a regulatory filing, Permian Resources CAO Brent Jensen disclosed the sale of 171,817 class A common shares of the company on September 5 at a price of $14.8302 per share.

17:35 EDT Boeing awarded $474.5M Air Force contract action - Boeing was awarded an undefinitized contract action with a total not-to-exceed value of $474.5M for the F-15 Japan Super Interceptor Program. This contract provides for the Foreign Military Sales, or FMS, requirement to add the Eagle Passive Warning Survivability System for the Japan Air Self Defense Force. Work is expected to be completed by December 31, 2028. This contract involves FMS to Japan. This contract was a sole-source acquisition. FMS funds in the amount of $76.39M are being obligated at time of award. The Air Force Life Cycle Management Center is the contracting activity.

17:33 EDT Guidewire says Q4 sales strength on track for $1B ARR - CFO Jeffrey Cooper states: "Finally, let me make a comment about our FY25 targets that we have been tracking for some time now. We will address this in more detail at our Analyst Day, but I wanted to make a comment quickly here. As Mike noted, we remain focused on achieving our target of $1 billion in ARR and the strength of Q4 sales activity demonstrates the path to achieving that goal. Total revenue is also tracking to our prior range. On the margin side, we're progressing a bit ahead of plan that we discussed at the last Analyst Day and our expectations for subscription and support gross margin, total gross margins, operating margins and cash flow from operations margins for fiscal 2025 and are now expected to finish closer to the high end of previously discussed ranges. We are thrilled with the progress we made in FY '23 to allow us to deliver increasing confidence towards our long-term targets." Comments taken from Q4 earnings conference call.

17:32 EDT General Dynamics to compete for orders on $488.66M Army contract - General Dynamics and Nammo Perry will compete for each order of the $488.66M fixed-price-incentive contract for manufacturing, assembly, inspection, packaging and delivery of 155 mm M119A2 propelling bag charges. Bids were solicited via the internet with two received. Work locations and funding will be determined with each order, with an estimated completion date of September 6, 2028. Army Contracting Command is the contracting activity.

17:18 EDT Fastly exec sells $2.09M in common stock - In a regulatory filing, Fastly disclosed that its Chief Architect Artur Bergman sold 87K shares of common stock on September 5th in a total transaction size of $2.09M.

17:02 EDT Hudson Pacific suspends common stock dividend - Hudson Pacific Properties announced that its Board of Directors suspended the company's quarterly dividend on its common stock, commencing with the third quarter dividend that would have been paid in September 2023. Chairman and Chief Executive Officer Victor Coleman said, "As we manage through current market conditions, including addressing the impact of the ongoing Hollywood strike, the Board believes that suspending our common stock dividend is a prudent decision."

16:59 EDT Carlisle announces process to sell CIT - Carlisle Companies that it is commencing a process to sell Carlisle Interconnect Technologies. CIT designs and manufactures high-performance wire and cable, including optical fiber for the commercial aerospace, military and defense electronics, medical device, industrial and test & measurement markets. CIT's product portfolio also includes sensors, connectors, contacts, cable assemblies, complex harnesses, racks, trays and installation kits. CIT also provides engineering and certification services to its customers. Chris Koch, Chair, President and Chief Executive Officer, said, "Our announced plan to sell CIT and completion of a transaction will be the final step in accomplishing Carlisle's pivot to a pure play building products company employing a superior capital allocation approach to investments. CIT is an excellent business operating in the highly desirable aerospace and medical segments with excellent growth prospects."

16:43 EDT Five9 exec sells $780K in common stock - In a regulatory filing, Five9 disclosed that its Product Engineering EVP sold 11K shares of common stock on September 5th in a total transaction size of $780K.

16:39 EDT Axcelis director Titinger sells 6,881 common shares - In a regulatory filing, Axcelis Technologies director Jorge Titinger disclosed the sale of 6,881 common shares of the company on September 7 at a price of $177.38 per share.

16:35 EDT Select Medical announces executive management appointments - Select Medical Holdings announced 12 executive management appointments, effective October 1. John Saich and Thomas Mullin have been promoted to co-presidents of the organization, and Michael Malatesta has been named Executive VP and CFO. A 26-year veteran of Select Medical, Saich most recently served as executive vice president and chief administrative officer overseeing its Outpatient Rehabilitation Division and Shared Services operations. Since joining Select Medical in 2008, Mullin has held operational leadership positions of increasing responsibility within the Critical Illness Recovery Hospital Division, including president. In 2018, his role expanded to the Inpatient Rehabilitation Hospital Division, serving as COO. A 24-year veteran of the company, Malatesta has served as senior vice president of finance since 2013 after holding a variety of senior finance and accounting positions within the Outpatient Rehabilitation Division. Each of these executives has been promoted to a new position: Michael Tarvin to senior executive vice president, general counsel and secretary; John Duggan to executive vice president and deputy general counsel; Tyler Hollenbach to executive vice president of strategy and growth; Mary Lacey to senior vice president and chief human resources officer; Shelly Eckenroth to senior vice president and chief communications, marketing and branding officer.

16:31 EDT Dave Chief Legal Officer John Ricci retiring, Joan Aristei suceeding - Dave announced that John Ricci, General Counsel, will retire on September 29. Joan Aristei has been named Chief Legal Officer, effective September 25. Joan Aristei most recently served as General Counsel and Chief Risk Officer at Oportun. Before Oportun, Aristei was Citigroup Private Bank's Head of Banking and Lending Product Compliance. She has also served as Vice President, Chief Compliance Officer, and Assistant General Counsel at JP Morgan Chase Auto and Student Lending division, and as counsel to Nissan Motors Finance and Toyota Financial Services.

16:19 EDT Codexis to realize $30M cash savings through 2031 after executing lease deal - Codexis announced the Company has executed an Assignment and Assumption of Lease for its San Carlos, California location. As a result of consolidating operations to its headquarters facility in Redwood City, California, Codexis estimates it will realize cumulative cash savings of more than $30M through 2031. The execution of the Assignment Agreement is consistent with the Company's ongoing strategy to focus resources on programs with the strongest commercial opportunity and greatest probability of near-term success, including the Company's enzyme-catalyzed oligonucleotide ECO Synthesis technology platform, designed to enable scalable production of RNA interference RNAi therapeutics. "The swift execution of this lease assignment demonstrates our ability to efficiently streamline the business and concentrate on the priorities we outlined in July as part of our enhanced strategic focus," said Kevin Norrett, MBA, Chief Operating Officer of Codexis. "Having the entire Company in one location will enable the close collaboration of our teams while also reducing overhead and positioning us to meet our projected cash runway to mid-2026."

16:18 EDT NextCure publishes review article on regulation of tumor immunity - NextCure announced the publication of a review article in the online journal Frontiers in Immunology, highlighting the need for targeting tumor collagen in the extracellular matrix, or ECM, in the tumor microenvironment to enhance anti-tumor immunity. The publication, titled "Regulation of Tumor Immunity and Immunotherapy by the Tumor Collagen Extracellular Matrix," details how ECM components, specifically collagen, have an active role in immune regulation when dysregulated. Collagen acts as a ligand and interacts with receptors on immune cells to inhibit immune cell subpopulations in the TME. Such interactions disable anti-tumor immune responses and promote tumor growth. In addition, the review highlights how the structural components of the dysregulated ECM create a physical barrier to immune infiltration, further impeding the overall immune response and contributing to tumor progression. The ECM is a major factor in facilitating not only tumor progression, but resistance to various therapeutic treatments, including immunotherapy. The review was published in collaboration with Nordic Bioscience A/S.

16:16 EDT Elanco says first shipments of Varenzin-CA1 conditionally approved by FDA - Elanco Animal Health announced that the first shipments of Varenzin-CA1, conditionally approved by U.S. Food and Drug Administration as the first and only treatment to control non-regenerative anemia in cats with chronic kidney disease, are shipping to veterinary clinics around the country. Anemia from CKD can dramatically affect a cat's existence, making them lethargic, reducing their appetite, and even leading to a rapid heart rate and difficulty breathing in severe cases. According to the FDA, CKD-related anemia is a complication that often contributes to death or euthanasia of affected cats due to poor quality of life. The challenges of current therapy to address this devastating condition often include inconvenient and extra-label use of a human drug. "Varenzin-CA1 is the first drug to receive conditional approval for use in cats, providing access to a novel medicine for our feline companions suffering from nonregenerative anemia due to CKD," said the FDA Center for Veterinary Medicine, upon conditionally approving the product. "Additionally, this is the first drug for cats under expanded conditional approval, a pathway to the marketplace that encourages development of innovative treatments and increases the options for treating animals with uncommon conditions, serious or life-threatening diseases, or diseases without existing or adequate therapies."

16:15 EDT Express names Stewart Glendinning CEO - Express announced that Stewart Glendinning has been appointed Chief Executive Officer and a member of the Express Board of Directors, effective September 15, 2023. Glendinning succeeds Tim Baxter, who has resigned as Chief Executive Officer and as a member of the Board. Baxter will be available as needed to support a smooth transition. Glendinning brings to Express more than 20 years of experience in the consumer products industry and a proven record of operating excellence, financial discipline and building high-performing teams to grow iconic brands. He most recently served as Group President, Prepared Foods of Tyson Foods, Inc. In this role, he managed all aspects of the Prepared Foods portfolio, including renowned brands Jimmy Dean, Hillshire Farm and Ball Park, and guided the business to strong volume performance and market share gains across the retail brand portfolio. Previously, Glendinning was Chief Financial Officer of Tyson Foods and responsible for worldwide financial planning, finance and accounting functions. "The Express Board is confident that Stewart is the right person to reinvigorate performance and build the strongest possible foundation on which Express can succeed," said Mylle Mangum, Chairman of the Express Board. "He is a highly accomplished executive who will bring fresh thinking to the Company and our strategies for profitable growth. Stewart shares the Board's belief that further operating improvements and greater financial discipline are needed to ensure that Express is best positioned to deliver significant, sustainable shareholder value."

16:14 EDT Equitrans Midstream CEO Karam to step down - Equitrans Midstream Corporation announced that Thomas F. Karam will step down from his role as chief executive officer of Equitrans Midstream (Equitrans or Company) to become the Company's executive chairman; and Diana M. Charletta, currently president and chief operating officer of Equitrans, will succeed Mr. Karam as Equitrans' newly appointed chief executive officer. The executive appointments are effective January 1, 2024, and both Mr. Karam and Ms. Charletta will continue to serve as members of the Equitrans Board of Directors following the leadership transition. "Nearly five years ago, Equitrans Midstream was launched as an independent, publicly traded company, and, since the beginning, we have been steadfast and resilient, persevering through challenges that many had thought were insurmountable," said Mr. Karam. "We are targeting completion of the Mountain Valley Pipeline project by year-end and believe this is the right time to execute on our long-planned leadership succession strategy. Equitrans has a long history, a comprehensive asset footprint across the Appalachian Basin, and a very bright future. With deep-rooted operational experience, Diana is a respected leader among her peers and across the organization, and I am confident in her ability to successfully execute on our strategic priorities."

16:13 EDT Limoneira now sees FY23 fresh lemon volumes 4.7M-5M cartons - The Company's food service business and industry logistics continue to experience slowdown due to supply chain and inflationary pressures on a global basis. The Company now expects fresh lemon volumes to be in the range of 4.7 million to 5.0 million cartons for fiscal year 2023, compared to previous guidance of 5.0 million to 5.4 million cartons. The Company achieved avocado volume of approximately 3.8 million pounds in fiscal year 2023 compared to previous guidance of 3.0 million to 4.0 million pounds. The Company expects to receive total proceeds of $115 million from Harvest at Limoneira, LLCB II and East Area II spread out over seven fiscal years, with approximately $8 million received in fiscal year 2022.

16:06 EDT Squarespace completes acquisition of Google Domains assets - Squarespace (SQSP) completed its acquisition of the assets associated with the Google (GOOG) Domains business, in accordance with the transaction agreement previously announced on June 15. With the acquisition now completed, Squarespace will, after a transition period, initiate the transfer of Google Domains accounts to its Squarespace Domains platform, leveraging Google's existing infrastructure during this period to ensure a transition to its domains platform. Squarespace will be increasing its investment in Squarespace Domains.

15:37 EDT BT Brands drops lawsuit against Noble Roman's, directors - BT Brands announced that it has withdrawn without prejudice its lawsuit in Federal Court for the Southern District of Indiana against Noble Roman's, or NROM, and its directors. BT Brands CEO, Gary Copperud, commented that the purpose of the lawsuit was to achieve a fair vote for Noble Roman shareholders. The company said, "We were not successful in our effort to get a ruling favorable to NROM shareholders as in its preliminary ruling, the Court allowed the annual meeting to proceed. Without the BT Brands proxy votes, NROM failed to attain a quorum and the election of a Class III Director was postponed to the 2024 annual meeting. The result is that three board seats will be elected in 2024, and we expect to nominate representatives for each available seat. The BT Brands lawsuit also alleged that the NROM and its Directors violated federal law in omitting material information from its Definitive Proxy Statement and that NROM and its Directors violated fiduciary duties by preventing BT Brands' nomination of Mr. Copperud, frustrating the expressed will of an overwhelming number of shares expected to vote at the annual meeting. We expect to further review these issues as part of an inspection of the NROM books and records and reserve the right to take further action as appropriate. Owning a combined stake of more than 8% of NROM shares, BT Brands sought to nominate Mr. Copperud to serve as a director of NROM to add a fresh perspective to its board, including reviews of policies concerning executive compensation and corporate borrowing. After it became clear that Mr. Copperud would defeat Mr. Scott Mobley, NROM deemed that Mr. Copperud's nomination was not in compliance with NROM's Bylaws and would not be considered valid."

15:11 EDT Tyson Foods says seeing sequential improvement into Q3 - Says seeing sequential improvement as it goes back through Q2 into Q3 and as company goes into the balance of this year and the next year. Says not satisfied with where company is just yet, but in the backdrop it has made some "pretty tough" moves that it expects will yield results, especially in the poultry segment. Comments taken from Barclays Global Consumer Staples Conference.

14:34 EDT Uber up 1% as company presents at Goldman conference - Uber's CEO discussed being in a "strong supply position" and said the company's advertising business is on track to exceed the company's $1B target for 2024, according to Bloomberg's coverage of comments made during the Goldman Sachs Communacopia + Technology Conference.

14:07 EDT AI valuable tool to aid in decision making, Bullfrog AI CEO says

14:07 EDT Bullfrog AI CEO says heavy focus on building pipeline

13:56 EDT Spirit CEO says 'probably going to be at low end' of Boeing guidance this year - Spirit AeroSystems CEO Thomas Gentile said while presenting at the Jefferies Industrials Conference, according to a transcript: "Well, we right now are starting to cycle at 42 aircraft per month. We've got 2 production lines in our plant. We can go up to 3, but we have 2 right now. Each produces 21 per month, so 1 a day. So we call it 2 1-day lines. So we load 2 each day, and we try to deliver to each day... In addition, on the 42 aircraft per month, we are now about aligned with Boeing in terms of production rate. And as we go into next year, we're going to finish this year at 42, we're going to go into next year at 42. So this year, our guidance was 370 to 390 aircraft on the max. We're probably going to be at the low end of that range given all the pressures and there's some pressure to that. But we're going to end this year at 42 aircraft per month. And we're going to be at 42 aircraft per month all of next year as will Boeing. And that's about 500 aircraft next year. And then in '25 and '26, Boeing has said they want to get up to 50 aircraft per month. And they've added a fourth line in Everett. So they're very serious about it, and they certainly have the backlog to support it. That would get us back up to 600 aircraft per month. So that's how we will align with them. We typically are about 6 months in advance of them. Because we're earlier in the production process. And so we start hiring even 10 to 12 weeks before that. So we have enough time to train our employees and also to get them on the job experience."

13:04 EDT UAW responds to General Motors, calls proposal 'insulting' - In response to General Motors' proposal submitted on September 7th, UAW President Shawn Fain said that, "After refusing to bargain in good faith for the past six weeks, only after having federal labor board charges filed against them, GM has come to the table with an insulting proposal that doesn't come close to an equitable agreement for America's autoworkers. GM either doesn't care or isn't listening when we say we need economic justice at GM by 11:59pm on September 14th. The clock is ticking. Stop wasting our members' time. Tick tock."Reference Link

12:45 EDT IMAC Holdings announces 1-for-30 reverse stock split - IMAC Holdings announced a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 and that it had filed a Certificate of Amendment to the company's Certificate of Incorporation in order to effect the Reverse Split. The Reverse Split will be effective after the market closes on September 7, 2023. Beginning with the opening of trading on September 8, 2023, the company's common stock will continue to trade on The Nasdaq Capital Market under the symbol "BACK," but will trade on a split-adjusted basis under a new CUSIP number, 44967K302.

12:30 EDT New Jersey Resources raises quarterly dividend 7.7% to 42c per share - The board of directors of New Jersey Resources Corporation unanimously approved a 7.7% increase in the quarterly dividend rate to 42c per share from 39c per share. The new quarterly rate will be effective with the dividend payable October 2, 2023 to shareowners of record on September 20, 2023. This dividend replaces the previously announced dividend of 39c per share approved on July 12, 2023 for shareowners of record on September 20, 2023. The new annual dividend rate will be $1.68 per share. NJR has paid quarterly dividends continuously since its inception in 1952, and has raised the dividend every year for the last 28 years. Steve Westhoven, President and CEO of NJR, stated, "Our long-term business strategy and financial position give the Board confidence to increase the quarterly dividend. We are committed to providing strong long-term returns to shareholders, and a growing dividend is a key component of increasing shareholder value."

12:12 EDT Xbox game 'Starfield' exceeded 1M concurrent players in launch day - Microsoft Gaming CEO Phil Spencer said that brand new Bethesda RPG "Starfield," which released in early access last week with an official launch on September 6, exceeded 1M concurrent players across Xbox Series and PC in day one. "Thanks to all the players who helped us reach this great milestone and congrats to the @BethesdaStudios," Spencer said. Reference Link

12:04 EDT Galectin Therapeutics to present data on liver cirrhosis at NASH meeting - Galectin Therapeutics announced today the company will participate in the 9th Edition of the Paris NASH meeting. This year, Galectin Therapeutics, in collaboration with HistoIndex of Singapore, will present a poster on the use of artificial intelligence to better explore the complex histology of liver cirrhosis resulting from NASH and highlight potential differences between lean cirrhotic patients and overweight/obese cirrhotic patients. Pol Boudes, MD, Chief Medical Officer of Galectin Therapeutics, commented: "Artificial Intelligence is an interesting tool that can improve the definition, description, and understanding of architectural changes in the liver tissue of cirrhotic patients. Current histology methods are not precise enough to be clinically relevant to stage the cirrhotic process and, consequently, are not generally used in clinical practice. Conventional histology is also not granular enough and not quantitative enough to evaluate the efficacy of candidate drugs. We are happy to contribute to the scientific progress in this field by sharing our data collected in our previous phase 2 cirrhosis program and by using the innovative technology that our colleagues at HistoIndex have developed."

12:02 EDT EA says new 'Madden' set single-week franchise record for digital units sold - Electronic Arts said its latest sports game "Madden NFL 24" set a single-week franchise record for digital units sold, saw a 36% increase in games played and drew more players during week one of launch compared to "Madden NFL 23." "We love seeing more players enjoying Madden NFL 24, and looking at all the ways they are exploring the new gameplay, new modes, and everything about this year's experience," said Mike Mahar, Senior Production Director, EA SPORTS Madden NFL. "NFL Kickoff means a brand new season of world class football competition is upon us, and alongside the big hits and game changing plays each week, our team will be hard at work bringing new content, experiences and improvements based on player feedback via live service updates all season long."

12:00 EDT General Motors says 'progressed to more detailed discussions' with UAW - General Motors says the company has "progressed to more detailed discussions in our UAW/GM labor negotiations, and today we put an economic offer on the table to the UAW." For "most employees" at max wage rate, the offer represents a 10% increase in wages, which GM calls "the largest wage increases since the 1999 contract and 67% higher than 2019 and 2015." Reference Link

12:00 EDT Phreesia falls -21.4% - Phreesia is down -21.4%, or -$6.48 to $23.87.

12:00 EDT Direxion Daily Semiconductor Bear 3X Shares rises 8.8% - Direxion Daily Semiconductor Bear 3X Shares is up 8.8%, or 82c to $10.19.

12:00 EDT Designer Brands rises 21.4% - Designer Brands is up 21.4%, or $2.22 to $12.60.

11:19 EDT WestRock, Smurfit Kappa in talks over key terms of potential combination - Last night, Smurfit Kappa (SMFKY) confirmed that the boards of directors of Smurfit Kappa and WestRock Company (WRK are discussing the key terms of a potential combination to create Smurfit WestRock. The Potential Combination would be expected to involve the creation of a new holding company, Smurfit WestRock. Smurfit WestRock would be incorporated and domiciled in Ireland with global headquarters in Dublin, Ireland and North and South American operations headquartered in Atlanta, Georgia. The Potential Combination would be effected through an Irish scheme of arrangement involving Smurfit Kappa and a merger of a subsidiary with WestRock. Any such combination would result in WestRock shareholders receiving consideration consisting primarily of shares of the Combined Group. Following completion of the Potential Combination: Smurfit WestRock's ordinary shares would be listed on the New York Stock Exchange and the Combined Group would seek U.S. equity index inclusion as soon as possible thereafter. Smurfit Kappa's premium listing on the London Stock Exchange is expected to be cancelled and the Combined Group is expected to list on the standard listing segment. Smurfit Kappa would de-list from Euronext Dublin. The Combined Group would be incorporated and domiciled in Ireland with global headquarters in Dublin, Ireland and North and South American operations headquartered in Atlanta, Georgia. Discussions between the parties remain ongoing regarding the Potential Combination. Smurfit Kappa and WestRock are engaged in a mutual due diligence process. The definitive terms and conditions of any transaction will be set out in a further announcement. Any Potential Combination would be conditional, inter alia, upon the approval by shareholders of Smurfit Kappa and WestRock and receipt of required regulatory clearances as well as other customary conditions. There can be no certainty that the Potential Combination or any other transaction between the parties will be agreed or will occur. This announcement has been made with the consent of WestRock. Further announcements may be made as and when appropriate.

11:10 EDT Vishay opens manufacturing facility in Gomez Palacio, Durango, Mexico - Vishay Intertechnology has opened a new manufacturing facility in Gomez Palacio, Durango, Mexico, where its initial activity will be mass production of power inductors - small electronic components that store and manage energy for handheld devices, computers, automotive electronics, and in many other applications. The new Vishay La Laguna S. de R.L. de C.V. is an 18,000 square meter, LEED v4-certified facility that will make a significant addition to Vishay's power inductor manufacturing capacity, which already includes production lines in the United States, Israel, and China. At Vishay La Laguna, the company has equipment and production lines set up and is presently conducting the internal and international standards qualifications that will allow Vishay to manufacture commercial product by the end of 2023. Production of Automotive Grade power inductors will follow in 2024.

10:46 EDT FMC calls Blue Orca's short report 'misleading,' shows inaccuracies - Speaking at the Jefferies Industrials Conference, FMC Corporation's EVP and CFO Andrew Sandifer said the company was aware of Blue Orca's short report on the company. "We're aware of the report and are reviewing it... There are inaccuracies, it is fraudulent and misleading," the executive said. Reference Link

10:41 EDT Grizzly says PDD 'a dying fraudulent company,' TEMU app 'hidden spyware' - In a recently published report, Grizzly Research "presents Smoking Gun evidence that PDD Holdings' widely downloaded shopping app TEMU is the most dangerous malware/spyware package currently in widespread circulation." "We strongly suspect that TEMU is already, or intends to, illegally sell stolen data from Western country customers to sustain a business model that is otherwise doomed for failure," the report reads. "TEMU is estimated to be losing $30 per order. Its ad spending and shipping costs (1-2 weeks from China, expedited to U.S. delivery) are astronomical. One is left wondering how this business could ever be profitable." Further, Grizzly says that, "PDD's financials are notoriously unreliable." Shares of PDD have dropped about 6% to $95.55 in Thursday morning trading. Reference Link

10:33 EDT Ryvyl trading resumes

10:23 EDT Ryvyl trading halted, volatility trading pause

10:15 EDT Grom Social Enterprises trading resumes

10:12 EDT Air Products to provide oxygen equipment for Jean-R-Marcotte plant - Air Products has been chosen by the city of Montreal to supply oxygen equipment to support an ozone generation site that will remove impurities from wastewater at the Jean-R-Marcotte Wastewater Treatment Plant. Jean-R.-Marcotte treats almost half of Quebec's wastewater before releasing it into the St. Lawrence River. On average, the wastewater treatment plant releases 2.3 million cubic meters of water into the river per day. As part of its agreement with the city of Montreal, Air Products will provide oxygen equipment, including four vacuum swing adsorption oxygen plants, to support the city's new state-of-the-art ozone generation system. The ozone generation system will disinfect the water, removing viruses, bacteria and pharmaceutical products.

10:10 EDT Acorn Energy announces 1-for-16 reverse stock split - Acorn Energy's Board of Directors has approved a reverse split of its Common Stock at a ratio of 1-for-16. The reverse split is intended to increase the market price of the Company's Common Stock and make Acorn's shares accessible to a broader range of investors, including institutions and those unable to purchase or recommend low-priced stocks.

10:07 EDT Peloton adds Peloton Row to product offerings in Canada - Peloton announced the Peloton Row will be available in Canada this holiday season. The addition of Peloton Row will bring a unique low-impact, full-body cardio and strength workout to the existing portfolio of Peloton equipment in the market, including Peloton Bike, Peloton Bike+, Peloton Guide and Peloton Tread. Peloton Row will be in all Peloton Showrooms across the country beginning this month for those who want to trial the equipment, before it is available for purchase. Once on-sale, Peloton Row will be available in all Canadian regions to which Peloton currently delivers.

10:04 EDT Beam Therapeutics presents preclinical data on BEAM-302 - Beam Therapeutics reported new preclinical data demonstrating the ability of its in vivo drug candidate, BEAM-302, to directly correct the PiZ mutation, the primary disease-causing mutation associated with severe alpha-1 antitrypsin deficiency. The data are featured in an oral presentation titled "BEAM-302: Targeting AATD Liver and Lung Disease with Base Editing" at the Alpha-1 Antitrypsin Deficiency 2023 Meeting in Naples, Italy. AATD is caused by mutations in the SERPINA1 gene, with greater than95% of severe clinical cases homozygous for the PiZ mutation. BEAM-302 is a liver-targeting lipid-nanoparticle formulation of base editing reagents designed to precisely correct the PiZ mutation, a single-letter genetic error. A one-time A-to-G correction of the PiZ mutation with Beam's adenine base editor has the potential to simultaneously reduce the aggregation of mutant, misfolded AAT protein that causes toxicity to the liver and increase circulating levels of corrected and functional AAT protein, thus addressing the underlying pathophysiology of both the lung and liver disease. Correction is expected to be durable based on preclinical evidence to date. Importantly, because the native AAT gene would be corrected in its normal genetic location, AAT levels would be anticipated to increase in response to inflammation or infection, an important aspect of normal AAT function, which does not occur with currently approved protein replacement therapies. BEAM-302 was evaluated in two preclinical species: an NSG-PiZ mouse model of AATD carrying multiple copies of the human PiZ allele and a novel humanized PiZ rat model developed by Beam scientists in which the normal rat AAT is replaced with human mutated PiZ AAT. Treatment with a single dose of BEAM-302 induced dose-dependent correction of the PiZ mutation. Clinically relevant doses up to 1mpk resulted in correction of up to 39% and 49% of liver DNA in rats and mice, respectively. Relative to pre-dose values, editing with BEAM-302 yielded two-times higher levels of total serum AAT and a 70% decrease in serum Z-AAT in rats. Editing with BEAM-302 yielded four-times higher levels of total serum AAT, and a 90% decrease in serum Z-AAT in mice. Relative to pre-dose values, editing with BEAM-302 yielded two- and three-times higher functional AAT in rats and mice, respectively, as indicated by the increased capacity of serum samples to inhibit human neutrophil elastase. Experiments with research-grade BEAM-302 demonstrated a reduction in toxic liver aggregates, also referred to as liver polymers. These findings support the potential of BEAM-302 to efficiently correct the disease-causal PiZ mutation after a single dose and potentially address both the liver and lung disease associated with AATD. Beam plans to submit a regulatory application for authorization to initiate clinical trials of BEAM-302 in the first quarter of 2024.

10:00 EDT Phreesia falls -18.4% - Phreesia is down -18.4%, or -$5.58 to $24.77.

10:00 EDT ChargePoint falls -28.8% - ChargePoint is down -28.8%, or -$2.03 to $5.03.

10:00 EDT Direxion Daily Semiconductor Bear 3X Shares rises 7.7% - Direxion Daily Semiconductor Bear 3X Shares is up 7.7%, or 72c to $10.09.

09:55 EDT Blue Orca says short FMC following 'recent string of stunning legal defeats' - Blue Orca says it is short FMC Corporation "because FMC has concealed from investors that it has suffered a recent string of stunning legal defeats around the globe that have enabled competitors to now launch competing generics at prices up to 80% below the price of FMC's flagship insecticide product. Contrary to the company's claims, FMC's process patents do not protect its flagship product from generic competition. The dam has broken." Blue Orca further states that, "FMC continues to misrepresent to investors that it will not face generic competition for its flagship diamides when in reality, as a result of devasting recent legal defeats, generics have already launched in key markets of India and China and are on the precipice of launching in Brazil. Our investigation found dozens of legal competitors, many industry heavyweights, who are, right now, manufacturing and selling generic versions of FMC's top selling insecticide product in FMC's most important markets at much lower prices... Given that FMC's patented diamides account for an estimated 60%+ of EBITDA, we expect that a tidal wave of generic competition on FMC's flagship product will crush FMC's revenues and profits while blowing out its leverage covenants. Accordingly, we doubt that FMC will be able to continue to roll commercial paper at absurdly cheap rates and we believe that like Enviva, an investment rating downgrade is likely. Ultimately, we believe that FMC is facing a perfect storm of both falling margins, shrinking revenues and crushing leverage." Shares of FMC have dropped over 2% to $80.32 in Thursday morning trading.Reference Link

09:47 EDT C3.ai falls -11.8% - C3.ai is down -11.8%, or -$3.73 to $27.73.

09:47 EDT Yext falls -22.4% - Yext is down -22.4%, or -$2.03 to $7.05.

09:47 EDT Wiley rises 8.7% - Wiley is up 8.7%, or $3.05 to $38.05.

09:45 EDT Aurora Cannabis launches Honour cultivar designed for veterans - Aurora Cannabis announced the launch of Honour, a new cannabis cultivar designed for veterans, by veterans and the second offering from Aurora's Strain for Heroes portfolio. Five per cent of net profits from the sale of Strain for Heroes products will be used to support veteran organizations across Canada. Honour, available under the MedReleaf brand, was selected with direct input from Canadian veterans. Aurora proudly welcomed Canadian veterans to the company's unique research and development facility in Comox, BC, for a firsthand, interactive experience with the cultivation program underway at the site. Honour and Valour strains were chosen from meaningful feedback from the veteran community and aim to provide veterans with the distinct cannabis experience they seek.

09:43 EDT Datasea enters agreements with two new clients for 5G messaging - Datasea announced that Datasea's Chinese operating entity, Shuhai Information Technology, together with Heilongjiang Xunrui Technology, Shuhai Jingwei Information Technology and Guozhong Times have entered into agreements with two prominent new clients: Hainuo Xintong Network Technology and Shenzhen Qiake Technology. These agreements enable Hainuo and Shenzhen Qiake to purchase 5G message virtual recharge cards in various denominations ranging from 10 to 500 RMB over the course of the 12 months of the agreements. In just the few short weeks since the agreements were signed with Hainuo and Shenzhen Qiake, Shuhai Beijing and its subsidiaries have provided 5G messaging top-up services valued at approximately $1.89 million. In addition to the new agreements, our ongoing services to pre-existing clients have generated approximately $1.06 million in revenue providing for the month of August alone.

09:40 EDT Dave Inc. trading resumes

09:38 EDT Boeing sees negative commercial, defense margins in Q3

09:37 EDT Rosecliff Acquisition Corp I trading resumes

09:36 EDT Boeing delivered 22 737s in August, says CFO

09:35 EDT Boeing CFO: Deliveries master schedule unchanged

09:33 EDT Boeing committed to long-term financial targets, says CFO

09:32 EDT Crown Electrokinetics completes purchase of micro trenchers - Crown Electrokinetics has placed an order for new micro trenchers which will be deployed with a new customer in Arizona.

09:30 EDT Amerant Bancorp announces new Broward County regional headquarters - Amerant Bank announced its commitment to a new Broward County Regional Headquarters. The office will be Amerant's 8th physical location in Broward County, on the heels of the opening of its brand new operations center in Miramar, FL. Amerant will occupy the new premises sometime in the second half of 2024. With this new location, Amerant Bank will now have approximately half of its 600 plus member workforce working in Broward County.

09:30 EDT Dave Inc. trading halted, volatility trading pause

09:29 EDT SciSparc initiates Phase 2b trial of Tourette Syndrome dandidate SCI-110 - SciSparc initiated its Phase IIb Clinical Trial for its proprietary SCI-110 for the treatment of Tourette Syndrome in Tel Aviv. The objective of this clinical trial is to evaluate the efficacy, safety and tolerability of SciSparc's proprietary drug candidate SCI-110 in adult patients using a daily oral treatment. The patients will be randomized at a 1:1 ratio to receive either SCI-110 or a SCI-110-matched placebo. The primary efficacy objective of the trial will be to assess tic severity change as a continuous endpoint at week 12 and week 26 of the double-blind phase compared to baseline. The primary safety objective of the trial is to assess absolute and relative frequencies of serious adverse events for the entire population and, separately, for the SCI-110 and placebo groups.

09:26 EDT Nano Dimension shareholders re-elect all director nominees - Nano Dimension announced that following its 2023 Annual General Meeting, Nano shareholders have voted to re-elect Nano's highly qualified director nominees - Dr. Yoav Nissan-Cohen, Col. Channa Caspi and Oded Gera - to the Company's Board of Directors. In addition, shareholders did not approve separate proposals put forth by Murchinson to remove other current directors. In addition, shareholders approved the reappointment of Somekh Chaikin, Certified Public Accountants, as the Company's independent auditor until the next Annual Meeting and have authorized the Company's Board of Directors to determine their compensation until the next Annual Meeting.

09:24 EDT Jamf Holding says more companies using Jamf to consolidate security tools - As companies work to find ways to save money during a fraught economy, more and more companies are turning to Jamf as the only platform that combines Apple management, identity, and security to protect devices and sensitive company data, while simplifying work and preserving privacy for end users. Organizations turning to Jamf are able to save money and resources by consolidating up to 18 different security tools and disparate workflows, including six device management, three identity management, and nine endpoint security tools.

09:22 EDT Rapid7, USF collaborate on cyber training intiative - Rapid announced that the company's proprietary threat data is powering a new research initiative investigating a better way to train cyber operators for maximum readiness. In partnership with the University of South Florida, this effort will be boosted by over $1.5M funding from the Office of Naval Research and the National Science Foundation.

09:20 EDT GE Aerospace selected by Bell for long-range assault aircraft - GE Aerospace (GE)announced the selection by Bell Textron a Textron (TXT) company, for work on the development of a Common Open Architecture Digital Backbone COADB , Voice and Data Recorder, and the Health Awareness System for the Bell V-280 Valor. Following the U.S. Army's Future Long-Range Assault Aircraft (FLRAA) program contract award, the V-280 Valor will enable the U.S. Army and its allies to maintain battlefield superiority including transformational capabilities in speed, range, payload, and endurance. The GE Aerospace systems will be part of an open, scalable, high-speed data infrastructure consistent with the U.S. Army's Modular Open Systems Approach that enables rapid testing, verification, and fielding of mission-focused capabilities for future vertical lift programs. "This is a foundational effort to improve weapon system capability and affordability for the Army by ensuring architectural alignment for integration of new technology," said Ryan Ehinger, senior vice president and program director for FLRAA at Bell. "This collaborative approach provides the Army a vendor-agnostic path to explore new systems and capabilities - delivering soldiers the right tools for success in multi-domain missions."

09:18 EDT Imperial Petroleum enters agreement to acquire two vessels for $71M - The Company also announced that it has entered into an agreement to acquire two tanker vessels, the aframax tanker Stealth Haralambos, built in 2009 and the product tanker Aquadisiac built in 2008, with an aggregate capacity of approximately 163,716 dwt. The aggregate purchase price for these acquisitions is $71 million. Both vessels will be delivered on a charter-free basis by the end of January 2024. The Company expects to finance the purchase price with cash-on-hand. The transaction with affiliates of the Vafias family, was approved by the Company's audit committee comprised of independent directors.

09:18 EDT Blink Charging awarded contract from state of Utah - Blink Charging has been selected as a State Contract Awardee by the Utah Division of Purchasing. The contract prioritizes Blink products and services for government, non-profit, K-12, and higher education agencies in Utah, preparing their properties and facilities for the growing demand for EV charging nationwide.

09:17 EDT IperionX to produce titanium plate for U.S. Army testing - IperionX Limited (IPX) has executed a Test Services Agreement and Statement of Work with the U.S. Army Combat Capabilities Development Command Ground Vehicle Systems Center DEVCOM GVSC . This agreement will focus on the metal characterization and ballistic testing properties of IperionX's high-strength titanium plate components. DEVCOM GVSC may relay the results to select U.S. DoD contractors who are original equipment manufacturers of U.S. Army ground vehicles for consideration in future ground vehicle designs. Known U.S. Army ground vehicle contractor OEMs include: General Dynamics Land Systems, an arm of General Dynamics (GD), BAE Systems he U.S. subsidiary of BAE Systems (BAESY) American Rheinmetall Defense, Oshkosh (OSK) ..The titanium plate for U.S Army ballistic testing will be manufactured using powder metallurgy production methods with IperionX's advanced titanium angular powder. To deliver higher performance and durability, IperionX will also employ its patented Hydrogen Sintering and Phase Transformation technologies, a cutting-edge technique to enhance the microstructure of titanium to deliver strength and fatigue properties that are comparable to wrought titanium alloys.

09:16 EDT Exela Technologies adds new customer for XME solution - Exela Technologies signed a new customer for its Marketing Execution solution, or XME. Exela's customer, a large regional healthcare provider, was using multiple vendors for print, promotional products and branded apparel leading to inefficiencies and escalating costs. Exela's XME solution will provide real-time reporting, inventory management, and print-on-demand enabling the elimination of over-inventoried items, reducing the cost of carry on their books and eliminating obsolete materials that needed to be discarded. The TCV of the contract is estimated at $7.5M and will be included in the ITPS segment which generated $765M of revenue in 2022.

09:15 EDT Galaxy Gaming, Konquer enter licensing agreement - Galaxy Gaming entered into a licensing agreement with Konquer to build and deploy Daredevil Poker(R), Emperor's Challenge Exposed, High Card Flush, and High Hand Blackjack in the North American market.

09:14 EDT Sorrento Therapeutics announces Phase 2a trial results for resiniferatoxin - Sorrento Therapeutics announced Phase 2a top-line clinical trial results for the RTX program. The Phase 2a study follows the positive observations from the Phase 1b/2 trial results of RTX Day 84 patient data, for which Sorrento has completed the one-year follow up for the last patient dosed in February 2021. The phase 2 trial, a multi-center, double blind, placebo- and active-controlled study, assessed the efficacy and safety of several dose groups of RTX to manage pain in patients with moderate-to-severe OAK. Given the durability of OAK pain relief response to RTX demonstrated in earlier phase 1b/2 trials, Sorrento decided to include an active approved comparator in the current trial protocol. Generally, treatment was well-tolerated, with the most common noted AE being pain following topical capsaicin 0.1% given to all patients for blinding purposes and study drug administration in the knee. Very few serious AEs were noted across all dose groups, with one in particular in the 15mcg RTX group being severe/life threatening, which resolved within hours with treatment of pain and no additional intervention. In the cases requiring pain control the dose of opioid was comparable. A few subjects in RTX groups required use of low dose oral opioids for up to 6 hours in some cases of prolonged moderate discomfort/pain. No patient required additional pain control or intervention after 6 hours or in the days following the day of administration and no patient left the clinic with opioids or an opioid prescription. Subject 008-005, a 55-year-old female with a prior history of hypertension and morbid obesity developed elevated blood pressure about fourteen minutes post-RTX dose, which coincided with severe pain. The subject received hydromorphone 0.8 and 0.4 mg IV and then oxycodone 5 mg twice, and the HTN resolved without any other intervention. The HTN did not recur, and the subject's ECG was normal. Discharge blood pressure was 140/74. Sponsor's medical monitor disagreed with the characterization as life-threatening or an SAE as the clinic stay was not prolonged and the HTN required no treatment other than treating the subject's pain. Sponsor also felt that the AE should have been considered a related event The RTX 20mcg dose group performed best among all dose groups, including placebo and approved intra-articular corticosteroid on short-term and prolonged pain relief measures. Although at many time points, RTX 20mcg was statistically significant as compared to the approved drug in this indication active control, we note that the study was not powered to demonstrate statistical significance for all end points listed, with only 120 patients enrolled across 5 RTX dose groups and early terminations due to the Company's previously announced bankruptcy proceedings. Despite the limitations of the study, the results = demonstrate that RTX 20mcg is an effective pain treatment for longer durations, with better score improvements at week 26 and 52 than the current standard of care up to and past week 26. A higher proportion of patients responded to treatment with RTX 20mcg than any other treatment group, including Zilretta. Reduction in pain was also more pronounced with RTX 20mcg than with any other treatment group, including placebo and active control. Durability of treatment was nearly twice as long for RTX 20mcg than active steroid control. In conclusion, we report that the phase 2a OAK study for RTX has met all the primary and secondary objectives for the study. The Phase 2a results were consistent with the prior safety profile of the drug from the previously completed Phase 1 study and has allowed for the potential determination of a therapeutically effective dose for further phase 2 pivotal or phase 3 studies, which is expected to be powered with a sufficient number of patients to provide significantly different results from the controls.

09:12 EDT Ansys announces global partnership with F1 in Schools organization - Ansys entered into a partnership with the F1 in Schools organization to provide CFD simulation solutions for participating student teams representing 58 countries. F1 in Schools creates a positive global impact on F1 and STEM by engaging students of all abilities in engineering competitions, while introducing future workforce skills and inspiring career opportunities.

09:10 EDT Ball Corp. CFO Morrison to retire, Yu named as successor - Ball Corporation (BALL) announced that Scott Morrison executive vice president and chief financial officer, will retire from the role after more than two decades with the company. Howard Yu has been named to succeed Morrison as executive vice president and CFO, starting Sept. 25. Morrison will remain with the company as a senior advisor to ensure a smooth transition and in support of the successful completion of the proposed Aerospace transaction. Yu most recently served as SVP and CFO for Envista (NVST), a publicly traded global company and spin-off of Danaher.

09:08 EDT Fazoli's opens in Orlando, Florida - Fazoli's is officially open in Orlando. Located at 4201 E. Colonial Dr., the location is owned by local operator Keys Restaurants Inc., and is now serving up its beloved hot and buttery breadsticks and signature Italian dishes including pasta, subs, salads, pizzas and more.

09:07 EDT Cardio Diagnostics, Truckers Health Network enter strategic collaboration - Cardio Diagnostics announced a strategic collaboration with Truckers Health Network, an organization providing health and wellness options to truckers and trucking companies. Truckers are disproportionately affected by heart disease and this partnership marks a significant commitment by both organizations to address the urgent need for heart disease prevention and control among trucking professionals. By combining Cardio Diagnostics' cardiovascular diagnostic offerings, remotely deployable on the road, at offices, and in warehouses, with Truckers Health Network's customized corporate wellness programming, the collaboration aims to exponentially expand the number of trucking professionals and trucking company staff with access to these crucial resources.

09:02 EDT Heart Test Laboratories signs distribution agreement with MedPhy Technologies - Heart Test Laboratories has extended its distribution channel through a new distribution agreement with MedPhy Technologies located in Mumbai, India. MedPhy Technologies will serve as HeartSciences' most recent distributorship fulfilling the role of both importer and distributor. Their network will provide HeartSciences with market representation across India once full product rollout has begun.

09:01 EDT Actinium presents updated survival data from Phase 2b trial of Actimab-A - Actinium Pharmaceuticals highlighted updated survival data from its Phase 1b trial evaluating Actimab-A in combination with the salvage chemotherapy CLAG-M in patients with high-risk relapsed or refractory acute myeloid leukemia and new preclinical data with Actimab-A in combination with FLT3 inhibitors at the Society of Hematologic Oncology, SOHO, 2023 Annual Meeting. In addition, results of the completed and positive Phase 3 SIERRA trial of Iomab-B were presented. SOHO Data Highlights: Updated Actimab-A + CLAG-M Phase 1b Study Results: 30-month median Overall Survival in patients with prior venetoclax treatment who proceeded to bone marrow transplant following Actimab-A + CLAG-M; 24-month median OS in all patients who proceeded to BMT following Actimab-A + CLAG-M; 100% measurable residual disease negativity in patients with prior venetoclax treatment and 75% MRD negativity in all patients; 83% of patients had high-risk r/r AML; 57% of patients (13/23) received prior treatment with venetoclax; Patients who relapse after venetoclax treatment have poor survival outcomes with a limited percentage of patients proceeding to BMT. Poster Title: Sequential Salvage Chemotherapy and Lintuzumab-Ac225 in Relapsed/Refractory AML Results in Deep Responses and Prolonged Survival in Adverse Risk Acute Myeloid Leukemia and in AML Patients that Received Prior Venetoclax Therapy. Actimab-A Program Expansion into FLT3 Mutant AML: actimab-A shown to have single-agent cytotoxic activity against FLT3 mutant AML cell lines; The addition of Actimab-A enhances the anti-leukemic activity of FLT3 inhibition of approved FLT3 inhibitors gilteritinib and midostaurin in vitro; FLT3 mutations are associated with aggressive disease with poor outcomes and occur in approximately 30% of patients, making it one of the most commonly mutated genes in AML; Combinations of Actimab-A with FLT3 inhibitors can potentially be explored under Actinium's CRADA with the NCI. Poster Title: Antileukemic Activity of Lintuzumab-Ac225 in Preclinical Model of FLT3 Mutant AML

08:57 EDT Aeglea BioTherapeutics announces 1-for-25 reverse stock split - Aeglea BioTherapeutics announced it will effect a reverse stock split of all outstanding shares of Aeglea's common stock at a ratio of 1-for-25. Aeglea expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on September 8, 2023. The reverse stock split was approved by stockholders during the annual meeting of stockholders on June 6, 2023 and by Aeglea's Board of Directors. The reverse stock split is intended to enable the company to meet minimum Nasdaq listing price per share requirements.

08:54 EDT Perimeter Medical Imaging AI provides updates on trial of OCT with ImgAssist AI - Perimeter Medical Imaging AI provided an update on the clinical development of its ongoing clinical trial evaluating the use of Perimeter B-Series OCT combined with its proprietary ImgAssist AI software during breast conservation surgery. Based on feedback from the U.S. Food and Drug Administration, FDA, the Company has reached alignment on key elements of the ongoing clinical trial, including the introduction of an interim analysis, which is expected in the second quarter of 2024. Adrian Mendes, Perimeter's Chief Executive Officer stated, "This positive interaction with the FDA marks an important milestone in our clinical development program. As a first step, we received regulatory approval to implement our substantially enhanced AI algorithm in the ongoing pivotal clinical trial under the existing study protocol, and we have now aligned on other key elements in order to chart a clear path forward for the development of our B-Series OCT with ImgAssist AI." Summary of Clinical Trial Updates : Clearance to introduce enhanced AI algorithm; Enrollment of additional subjects; Introduction of interim analysis within study protocol; Additional clinical trial sites permitted; Summary of anticipated AI improvements

08:53 EDT CNS Pharmaceuticals reaches enrollment of 200 patients in berubicin study - CNS Pharmaceuticals announced that 200 of the expected 243 patients have now been enrolled in the Company's ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer. This potentially pivotal, global study of Berubicin is an adaptive, multicenter, open-label, randomized controlled study in adult patients with recurrent GBM after failure of standard first-line therapy and compared to Lomustine as the standard of care. The primary endpoint of the study is Overall Survival, a rigorous endpoint that the FDA has recognized as the basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm. The Company has opened 46 clinical trial sites of the approximately 60 sites selected across the U.S., Italy, France, Spain, and Switzerland. As previously announced, CNS Pharmaceuticals has reached the criteria required by the study protocol to conduct a pre-planned, non-binding futility analysis, which an independent Data Safety Monitoring Board will review to determine whether to recommend continuing the study as planned or modifying the study based on Berubicin showing potential value as a second-line treatment for patients with glioblastoma. CNS Pharmaceuticals previously reported that the Company would conduct this analysis after at least 50% of the patients in the population to be analyzed for the interim analysis had reached the primary efficacy endpoint, as provided for in the study protocol. The DSMB will review the number of deaths in each arm to ensure that the overall survival of patients receiving Berubicin shows at least a statistically significant comparability to those receiving Lomustine. Additional analyses will include comparisons of secondary endpoints, including progression-free survival, response rates, and safety assessments. The Company is confident it will announce the results from the interim analysis publicly before the year end. Enrollment will continue during the interim analysis.

08:51 EDT RB Global's SmartEquip unveils e-commerce store 2.0 platform - RB Global announced that its subsidiary SmartEquip has released a major enhancement to its digital parts commerce product. The new SmartEquip e-Commerce Store 2.0 platform can help dealers, fleet owners and authorized distributors in the industrial goods industry to set up a branded, digital parts shop quickly and easily. "We were able to listen to customers during the beta program and have introduced a slate of new features based on their feedback," said Matt Ackley, Chief Digital Officer at RB Global. "This is just another example of how we are expanding the scope of our platforms to meet the needs of our customers across the industry."

08:50 EDT SKYX Platforms announces issuance of three patents for modular platform tech - SKYX Platforms announced the issuance of three new patents in the U.S., Europe and Japan for the Company's plug-and-play, all-in-one smart modular platform technology for ceilings in homes and buildings. The three additional patent issuances cover the smart home and related home safety sensors, bringing the Company's intellectual property portfolio to a total of 72 issued and pending patents, 18 of which are issued patents covering SKYX's advanced and smart technologies.

08:49 EDT Bristow Group, Volocopter to bring UAM services to U.S., U.K. - Bristow Group have signed an agreement to explore and develop passenger and cargo services for electric vertical takeoff and landing, eVTOL, aircraft in the U.S. and U.K. As part of this collaboration, Bristow has placed a firm order for two VoloCity aircraft to be delivered after certification with an option to purchase a further 78 vehicles in the future. Both parties will begin immediate cooperation to build a UAM ecosystem that includes regulatory discussions, infrastructure exploration, and local partnership building. The joint development agreement covers the exploration of commercial, operational, and eVTOL aircraft maintenance services, including adaptation of the VoloIQ, Volocopter's proprietary digital platform, to ensure Bristow's efficient future operations.

08:48 EDT Century Lithium obtains provisional patent - Century Lithium reports it has obtained a provisional patent with the U.S. Patent and Trademark Office, U.S. Department of Commerce. The provisional patent is titled System and Method for Extracting Lithium from Clay and Other Materials in a Chloride Solution Using Individualized Pretreatments. The patent pending process encompasses the Company's flowsheet, as developed at its Lithium Extraction Facility in Amargosa Valley, Nevada, USA and protects the Company's intellectual property pertaining to the handling of solutions derived from the treatment of solid materials including clays from the Company's Clayton Valley Lithium Project in Nevada. "Through the excellent work of Century Lithium's team, we have developed a system for lithium extraction which is proprietary to the Company" said Bill Willoughby, President, and CEO of Century Lithium. "Our system incorporates innovations made during our team's work at the Pilot Plant. The provisional patent provides protection of our system and its IP as we move forward with our Feasibility Study."

08:47 EDT CN Energy secures activated carbon order for $1.64M - CN Energy Group announced that its wholly-owned subsidiary, Hangzhou Fulaisen Science and Technology closed on an order for activated carbon totaling RMB 12 million, equivalent to approximately US $1.64 million. Hangzhou Forasen Technology Co., Ltd. was recognized as the preferred supplier. Xinyang Wang, CNEY's Board Chairwoman, commented, "We appreciate the trust of our clientele. We have guaranteed the timely fulfillment of the order, in addition to providing high-performance and reputable activated carbon commodities, along with professional and comprehensive after-sales service. In the meantime, we will continue to pursue additional market opportunities, expand our core market strengths, create value for clients with innovative products and advance the implementation of the corporation's long-term strategy of expanding our client base globally."

08:46 EDT Huntington Bancshares invested in Veuu - Huntington Bancshares Incorporated has invested in Veuu to develop artificial intelligence-based solutions to revenue cycle challenges common within the healthcare industry. The investment brings together Huntington's healthcare banking experience and Veuu's AI expertise. "For years, we've heard from our physician and hospital clients about the difficulties they experience with the revenue cycle and limitations to working capital financing, so we decided to team up with Veuu to develop solutions that address the complex root cause: medical coding errors," said Dan Storer, Huntington's senior managing director of healthcare banking. "No single stakeholder in healthcare can solve the downstream consequences like claim denials and expensive financing options-not the providers, payors, government, technology companies or financial institutions. These digital innovations require collaboration and strong partnership, and our relationship with Veuu strategically positions us to be able to tackle many of these challenges."

08:41 EDT Crispr Therapeutics Chairman Rodger Novak stepping down, CEO Kulkarni succeeds - Crispr Therapeutics announced that Rodger Novak, President and Chairman of the Board of CRISPR Therapeutics, has elected to leave the company after nearly a decade of service, effective as of September 15. As of that date, Samarth Kulkarni, CEO, will succeed Novak as Chairman of the Board and will continue serving as CEO of the company.

08:39 EDT Bitdeer provides August 2023 operations update - Bitdeer announced its unaudited mining and operations updates for August 2023. During August, the Gedu Datacenter entered full operations with approximately 30,000 mining machines energized. This boosts aggregate electrical capacity by 100MW and adds approximately 3.3EH/s to proprietary hash rate. The company mined 383 Bitcoins through its self-mining business in August, representing annual and monthly increases of 124.0% and 74.1%, respectively. Proprietary hash rate as of August 31 increased by approximately 0.8 EH/s from 7.9 EH/s as of July 31, primarily attributable to the arrival of approximately 7,000 additional mining machines at the company's Gedu mining datacenter in Bhutan. As of the end of August, the Gedu Datacenter's entire 100MW electrical capacity had been deployed.

08:36 EDT Workhorse Group begins production of W56 Chassis - Workhorse Group has started production of the chassis for its W56 electric vehicle at the Company's Union City, Indiana manufacturing facility. The W56 is the Company's first fully-designed, purpose-built Class 5/6 model chassis platform built from the ground up. Workhorse expects to begin production of full W56 step vans later in September and to have production quality demo units delivered to major fleets early in the fourth quarter.

08:36 EDT Clean Energy Technologies affiliate signs Power Purchase Agreement with VEPP - Clean Energy Technologies announced a 20-year Power Purchase Agreement, or PPA, between Vermont Renewable Gas, a limited liability company affiliated with CETY and VEPP, a not-for-profit corporation that administers two of Vermont's Renewable Energy Programs under contract with the Vermont Public Utility Commission. VRG will exclusively sell all electric power and other related benefits from its 2.2 MW biogas facility in Lyndonville, Vermont, to VEPP. The deal, anchored by the Lyndonville project's anticipated generator availability, is valued at $53M. VEPP will distribute renewable energy and other benefits from the VRG project to Vermont's 17 electric distribution companies.

08:34 EDT SunCar Technology expands overseas car services - SunCar Technology Group has renewed its one-year overseas airport pickup service agreement with Bank of Communications Limited, the 5th largest bank in China. SunCar's overseas airport service covers 213 overseas airports around the world, including in the United States, the United Kingdom, Canada, Spain, Italy, Japan, and Australia. For elite institutional customers such as BoComm, SunCar is the top choice for value-added services during business travel at home and abroad. With the continued recovery of overseas travel post-COVID, SunCar expects to seize this opportunity to continue expanding its overseas car services.

08:33 EDT HeartCore Enterprises engages Marushin to license task mining solution - HeartCore Enterprises has signed a deal with Marushin to implement its task mining software solution, Controlio, into Marushin's network of digital systems. Having been in operations for almost six decades, Marushin works within the logistics, licensing and development of towel products in Japan. More recently, Marushin has engaged major studio companies such as Studio GHIBLI, The Walt Disney Company, and Warner Bros. Controlio is HeartCore's task mining tool that captures and records all operations that users perform on their PCs, one operation at a time, and analyzes them appropriately to visualize the details of their operations.

08:31 EDT Acentra Health awarded contract extension for Florida Medicaid - Florida's Agency for Health Care Administration awarded Acentra Health a new five-year contract extending the company's 12 years of work overseeing utilization management services for beneficiaries enrolled in the state's fee-for-service Medicaid program and those receiving select Medicaid Managed Care carve-out services.

08:30 EDT Ensysce Biosciences to present clinical data at PAINWeek - Ensysce Biosciences is presenting clinical data at PAINWeek, the leading US pain conference, today, September 7, 2023, in Las Vegas, NV. America remains gripped by the opioid epidemic and this is creating another looming crisis: patients deprived of access to medication for severe pain. Ensysce is working to address both crises by developing unique and safer opioid products. Today the Company is presenting their groundbreaking approaches at PAINWeek 2023. This scientific session will explore the latest information on severe pain treatment, the ongoing issues with current products on the market, and examine the safety and effectiveness of two 'Next-Generation analgesics' from Ensysce Biosciences, PF614 and PF614-MPAR. The faculty is comprised of world experts in the field, featuring Dr. Jeff Gudin, a Pain Physician at the University of Miami. The data being presented builds a picture of unique safety combined with powerful pain relief, charting the progress of these drugs in development from animal models to compelling human clinical data. The latest data being presented will highlight the Ensysce approach to reduce prescription drug overdoses, an approach that could herald a first for the industry.

08:29 EDT Arcutis Biotherapeutics' roflumilast cream shows efficacy in atopic dermatitis - Arcutis Biotherapeutics announced interim results from the INTEGUMENT-OLE long-term open-label study of roflumilast cream 0.15% in adults and children ages 6 years and older with atopic dermatitis. In the study, roflumilast cream was well-tolerated, with no new safety signals observed during treatment up to 56 weeks in duration. Efficacy was not only maintained but improved over time, with 46.1% and 51.0% of participants who rolled over from the roflumilast cream treatment arm in INTEGUMENT-1 or -2 achieving validated Investigator Global Assessment-Atopic Dermatitis success. Additionally, in the study, 61.5% and 66.2% of participants who rolled over from the roflumilast cream arm in INTEGUMENT-1 or -2 demonstrated a 75% improvement from baseline in Eczema Area and Severity Index after 28 weeks and 56 weeks, respectively. The long-term study results reinforce the safety profile of roflumilast cream already seen in the short-term INTEGUMENT-1 and INTEGUMENT-2 clinical trials, with no new safety signals observed up to 56 weeks. 3.0% of trial participants discontinued the study due to adverse events. Arcutis intends to submit a supplemental New Drug Application late in Q3 for roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis in individuals ages 6 years and older.

08:28 EDT SOBRSafe secures first rehabilitation customer Oceanfront Recovery - SOBR Safe has secured its first alcohol rehabilitation customer, Oceanfront Recovery. Based in Laguna Beach, California, Oceanfront has installed SOBRcheck at its headquarters, and has deployed SOBRsure for continuous client monitoring. In addition, Oceanfront President and COO Keenen Diamond has joined SOBRsafe as a Strategic Advisor, helping SOBRsafe gain industry exposure and adoption.

08:25 EDT Microchip launches MPLAB Machine Learning Development Suite - Microchip Technology has launched a complete, integrated workflow for streamlined ML model development with its new MPLAB Machine Learning Development Suite. This software toolkit can be utilized across Microchip's portfolio of microcontrollers and microprocessors to add an ML inference quickly and efficiently.

08:20 EDT Ardelyx reports employee inducement grants - Ardelyx announced that on September 6, 2023, the compensation committee of the company's board of directors granted two new non-executive employees options to purchase an aggregate of 65,828 shares of the company's common stock, and granted three new non-executive employees an aggregate of 39,550 Restricted Stock Units. Each stock option has an exercise price per share equal to $4.73 per share, which was the closing trading price of the company's common stock on the date of grant. The stock options and RSUs were granted as inducements material to each employee's decision to enter into employment with Ardelyx, in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the employee's first date of employment, and the remaining 75% of shares vesting monthly thereafter. Each RSU vests over four years, with 25% vesting on the first company designated quarterly RSU vest date following the first anniversary of the employee's first day of employment and the remaining 75% of shares vesting quarterly thereafter. Each stock option has a 10-year term and each option and RSU is subject to the terms and conditions of the company's 2016 Employment Commencement Incentive Plan and the award agreement covering the grant.

08:19 EDT Worksport announces solar panel supply partner for SOLIS - Worksport announced that it has found a solar panel provider for its SOLIS Solar Tonneau Cover. This partner is renowned for their solar panels and underlying technology. A supply partner will help set a new standard in renewable energy tech for vehicles and to provide the most durable and highest quality flexible solar panels. With this supply partner for SOLIS, the Company is demonstrating its unwavering commitment to pioneering sustainable technological solutions. The sample solar panels presented to Worksport and tested in Worksport's SOLIS Solar Cover epitomize resilience and innovation. Adhering to rigorous environmental and structural standards, these panels incorporate high-quality components for extended durability. Designed to withstand wind, water, and direct impact, they showcase versatility and resilience in all tested elements and extreme weather, use case scenarios. Featuring corrosion-resistant structures and a marine-engineered photovoltaic module with a long lifespan, they also boast UV resistance and superior flexibility. This top-tier partner underscores Worksport's dedication to blending excellence with sustainability.

08:18 EDT Salesforce, McKinsey collaborate for AI-powered growth - McKinsey & Company and Salesforce announced a new collaboration to accelerate the introduction of trusted generative AI for sales, marketing, commerce, and service. This collaboration will bring together Salesforce customer relationship management technologies, including Einstein and Data Cloud, with McKinsey's proprietary AI and data models, assets, and capability building power. Together McKinsey and Salesforce will help companies connect relevant structured and unstructured data to improve customer buying experiences, increase sales productivity, personalize digital marketing campaigns and reduce call resolution time.

08:17 EDT IBM announces plans for new AI models, enhancements coming to watsonx - IBM announced plans for new generative AI foundation models and enhancements coming to watsonx - its AI and data platform with a set of AI capabilities designed to help enterprises scale and accelerate the impact of AI. These enhancements include a technical preview for watsonx.governance, new generative AI data services coming to watsonx.data, and the planned integration of watsonx.ai foundation models across select software and infrastructure products.

08:15 EDT Harmony announces U.S. FDA granted Orphan Drug designation to pitolisant - Harmony Biosciences announced that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug designation to pitolisant for the treatment of idiopathic hypersomnia, IH. Harmony is currently evaluating the efficacy and safety of pitolisant in adult patients with IH in the Phase 3 registrational INTUNE study, a double-blind, placebo-controlled, randomized withdrawal study. Topline study results are anticipated in the fourth quarter of 2023 following enrollment completion nine months ahead of plan. "The FDA's decision to grant Orphan Drug designation reinforces our belief in pitolisant as a promising therapy for adult patients with IH, with the unique added benefit of it being a non-scheduled, once-daily treatment option working through histamine to improve wakefulness," said Kumar Budur, M.D., Chief Medical Officer at Harmony Biosciences. "With the completion of enrollment in our INTUNE study nine months ahead of schedule and topline results expected in Q4, this designation is a significant advance in our clinical and commercial development initiatives. We look forward to working closely with the FDA and the broader IH community to address the unmet medical needs of patients living with this condition."

08:14 EDT Ford announces pay increase for 8,000 UAW employees - Nearly 8,000 UAW-represented Ford employees received a substantial raise this Labor Day. On average, these employees now earn $4.33 more per hour, or $9,000 a year. The increase could top $10,000 a year with overtime. The pay hikes were negotiated by Ford and the UAW in 2019 to shorten the time it takes workers to reach the average top wage rate of $32 an hour. Normally, growing into the top wage rate takes eight years, but with this agreement, 8,000 employees reached the top wage rates with as little as four years on the job. The top wage rate differs by the specific type of job an employee does. On average, it is $32 per hour. With this move, 80% of all Ford's UAW-represented hourly employees are now at the top wage rate. Those at the top wage rate are earning higher wages than 90% of all hourly employees in the U.S. auto industry, according to data from the Bureau of Labor Statistics. Permanent hourly manufacturing employees were eligible for the pay increase if they were hired prior to the 2019 contract effective date and were earning at least $24.40 per hour as of Sept. 1. Employees will see the pay increase in their next paystubs. Ford has exceeded its job and investment commitments for the last three contracts, recently creating or retaining 5,600 jobs beyond 8,500 committed and investing $1.4B beyond $6B committed in the 2019 contract. The company converted more than 14,100 employees from temporary employment to full-time permanent roles during the past four years - most of them ahead of schedule - and made all new hourly employees eligible for health care benefits from their first day on the job effective June 13, 2022. Ford launched a $1B five-year plan to upgrade the workplace experience in its plants, starting in 2022, providing better food service, mother's stations, upgraded restrooms and more

08:13 EDT Arcimoto to unveil new variation of MUV at Del Mar Wine + Food Festival - Arcimoto announced it will showcase a new variation of the MUV at the Del Mar Wine + Food festival this weekend, Sept. 9-10. Attendees can experience the custom MUV at the Gwynn Foods . and AleSmith booth #13, located in the Locally Made Zone. The all-new MUV variation, equipped with an enclosed cargo box to house a cold keg, tap system and two tap handles, showcases one of the numerous applications of the vehicle. The all-electric MUV, built on the company's flagship FUV platform, provides optimal performance for industrial, commercial and ground support applications for customers who need to move goods, materials, supplies and equipment reliably, quietly and sustainably.

08:12 EDT Lowe's renews its multi-year contract with the NFL - Lowe's announced the renewal of its multi-year contract with the NFL for the 2023 season. "With the return of the NFL season, Lowe's wants everyone - whether they're our DIY and Pro customers or NFL stars - to feel equipped to take on home improvement projects and support the communities they love," said Jen Wilson, senior vice president, enterprise brand and marketing. "At the intersection of Lowe's customers and the NFL's ever-growing loyal fanbase, we know there is an audience of first-time DIYers who want to put the sweat equity into their home but don't always feel they have the skills. We are excited to kick off the season with an integrated marketing campaign that continues positioning Lowe's as an empathetic, problem-solving brand that has our customers' backs."

08:11 EDT Honeywell leverages quantum-computing encryption keys - Honeywell announced that it is the first company to integrate quantum-computing-hardened encryption keys into smart utility meters, helping protect end-user data from advanced cybersecurity threats. Honeywell will utilize Quantinuum's Quantum Origin technology to help increase reliability and trust in the digitally transforming utilities sector. "By integrating Quantinuum's quantum-computing-hardened encryption technology into our smart meters, we're advancing data security for our customers and helping to shape the dialogue on how the utility industries should approach cybersecurity in the quantum era," said Hamed Heyhat, President of Smart Energy and Thermal Solutions at Honeywell. "This integration underscores how continuous innovation enables customers to stay ahead of the evolving threat landscape. It is a level of protection that is vitally important in our increasingly digital and interconnected world."

08:10 EDT Clubhouse Media closes promo deal with Keyshawn Johnson - Clubhouse Media Group finalized a brand promotional deal with Keyshawn Johnson. Johnson had an impressive career, spanning eleven NFL seasons. He was one of only three wide receivers to be taken first overall in the NFL draft. Johnson would go on to be a Super Bowl Champion and three-time Pro Bowler. He played for various teams, ending his career with the Carolina Panthers. Following football, Johnson became a broadcaster for ESPN and one of the co-hosts of the weekday morning debate show "Undisputed" with Richard Sherman, Michael Irvin and Skip Bayless.

08:09 EDT Pagaya teams with automotive fintech company Westlake Financial - Pagaya Technologies has announced a partnership with Westlake Financial, an automotive fintech company with almost $24B in assets under management, originating indirect automotive retail installment contracts through a nationwide network of new and used auto dealers...By tapping into Pagaya's innovative tech-enabled credit-analysis platform, the partnership with Westlake will facilitate smarter, more empowered credit decisions that will elevate the car-buying experience, creating more loans for more customers. "Pagaya's credit scoring is very complementary to Westlake's decisioning model," stated Chris Urban, SVP of Risk for Westlake Financial. ..."In an increasingly competitive credit market, Pagaya is helping our partners approve more loans, thereby helping their dealerships sell more cars and trucks. "We're excited to be leveraging Pagaya across more of our dealerships, optimizing the financing experience for car buyers," said Don Hankey, Chairman of the Board of Hankey Group, the parent group of Westlake Financial. "Pagaya's AI technology and two-sided lending network allows us to unlock new opportunities for our team and facilitate seamless transactions, ultimately helping our dealers sell more, and our customers get approved faster

08:09 EDT Elicio Therapeutics receives $2.6M grant for two therapeutic cancer vaccines - Elicio Therapeutics has been awarded a $2.6M grant from the GI Research Foundation in Chicago to fund research for two therapeutic cancer vaccines, ELI-007 and ELI-008. This $2.6M grant is an addition to the $2.8M that it awarded Elicio in September 2022. Funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting several mutations. Both vaccines have been designed with Elicio's proprietary lymph node-targeting Amphiphile platform. This additional funding will help support the completion of all manufacturing, regulatory and clinical preparation needed to continue to move ELI-007 and ELI-008 forward. The grant will enable Elicio to pursue initial patient clinical assessment.

08:08 EDT Artelo Biosciences completes Pre-IND meeting with FDA for ART26.12 - Artelo Biosciences announced it has completed a pre-IND meeting with the U.S. Food and Drug Administration regarding the manufacturing, preclinical and clinical development plan for ART26.12. Based on the FDA's feedback, the Company also announced that it plans to file an IND application for the use of ART26.12 in neuropathic pain in the first half of 2024. ART26.12 is a potential first-in-class orally administered Fatty Acid Binding Protein 5 inhibitor drug, initially under development for the prevention of chemotherapy-induced peripheral neuropathy, a debilitating and often treatment-altering side effect of cancer therapy. The FDA reviewed the IND-enabling preclinical data, manufacturing plans, and clinical study protocol synopses, provided guidance, and answered Artelo's questions on the development plan.

08:08 EDT NuZee appoints C.A. Fortune for sales, marketing Stone Brewing coffee products - NuZee announces the appointment of C.A. Fortune, a consumer brands agency based in Chicago, Ill., to spearhead sales and marketing of Stone Brewing specialty coffee products. "C.A. Fortune has an impeccable track record in providing a full suite of sales and marketing services for a wide array of commercial brands across the grocery and specialty foods spectrum," commented Masa Higashida, NuZee's CEO. "They are well versed in helping brands gain distribution in top retailers while also helping to generate awareness across a variety of verticals."

08:06 EDT Illinois Tool Works announces CEO succession plan - Illinois Tool Works announced a succession plan. Christopher O'Herlihy, currently Vice Chairman of ITW, will become President and CEO and a member of the ITW Board of Directors, effective January 1, 2024. Scott Santi, ITW's CEO since 2012, will step down as CEO and will remain Chairman of the ITW Board until March 1, 2024, at which time he will become Non-Executive Chairman of the ITW Board. O'Herlihy has been with ITW for over 34 years. He was named Executive VP of the company's Food Equipment Group in 2010 and elected Vice Chairman in 2015. He serves on the Board of Directors of Masco Corporation. Santi first joined ITW as a summer intern in 1982. He was elected CEO in 2012 and Chairman in 2015.

08:04 EDT National MI integrates with Calyx Point LOS - National Mortgage Insurance Corporation is now integrated with Calyx Software's Point loan origination system. The integration enables lenders and brokers to order National MI's real-time, risk-based mortgage insurance through its Rate GPS tool instantly without having to leave the Point platform.

08:03 EDT Genasys announces $1.6M in LRAD orders from U.S. DOD - Genasys announced new Long Range Acoustic Device orders valued at $1.6 million from the U.S. Department of Defense. These orders will deliver LRAD-1950XLs to the United States Special Operations Command in Europe, LRAD 360-XT mobile communications trailers to the U.S. Navy in Africa, and various spares to Navy units in the United States.

07:59 EDT Philips reaches resolution of U.S. economic loss litigation - Royal Philips announced that the company and certain of its US subsidiaries, including Philips Respironics, have reached an agreement to resolve all economic loss claims in the US Multidistrict Litigation related to Philips Respironics' voluntary recall of certain sleep and respiratory care devices. This settlement, which is expected to be submitted to the US District Court for the Western District of Pennsylvania later today, does not include or constitute any admission of liability, wrongdoing, or fault by any of the Philips parties. The agreement, which is subject to approval by the court, will provide predefined cash awards to all eligible participants in the US depending on the type of device, extended warranties on all replacement devices, and an additional cash award if they return the recalled device to Philips Respironics. The settlement will further compensate certain individuals who acquired replacement devices post-recall. The final cost of the settlement may vary based on, among other things, how many patients participate in the settlement and what the Court awards for the professional fees relating to the resolutions. Philips Respironics has recorded a provision for an amount of EUR 575M in the first quarter of 2023 to cover for the estimated costs of the final settlement. Subject to final Court approval, payments to class members under the settlement are not expected to begin until the first quarter of 2024 at the earliest. The agreement does not settle any personal injury or medical monitoring claims in the MDL, which the Philips parties have moved to dismiss.

07:48 EDT Palatin completes enrollment in Phase 3 MELODY-1 study of PL9643 - Palatin Technologies announced that enrollment in the PL9643 MELODY-1 Phase 3 study in dry eye disease is complete, with 570 patients enrolled. The Company is on track to release topline results by the end of the fourth quarter of calendar year 2023. "We are committed to addressing unmet needs of DED patients. We believe that PL9643, with its novel mechanism of action and differentiated product profile for efficacy, safety and ocular tolerability, if approved, will be a first-in-class treatment option for the millions of patients who suffer from DED," said Carl Spana, Ph.D., President and CEO of Palatin. "We are optimistic about results of the Phase 3 PL9643 data based on the positive interim analysis and are pleased to have completed enrollment so promptly. I thank the patients, investigators, clinical site staff, and our employees for achieving this important milestone." Topline data for the PL9643 MELODY-1 Phase 3 Study is anticipated by the end of the fourth quarter of calendar year 2023.

07:39 EDT ARway.ai secures contract with Suleyman Demirel Universitesi - ARway.ai announces a newly signed contract with Suleyman Demirel undefinedniversitesi situated in Isparta, Turkey. The university currently has approx 70,000 students enrolled, making it the second-largest academic institution in Turkey. This new contract has two phases with phase one starting at around $10,000 and phase two worth six figures annually.

07:36 EDT Sapiens announces a tier-1 bank in South Africa is extending its relationship - Sapiens International announced that a tier-1 bank in South Africa, a long standing customer of Sapiens, is extending their use of Sapiens CoreSuite for Life & Pensions to launch their Group Risk proposition. "We are proud that the bank chose to expand its relationship with Sapiens because of their trust in our established track record and our live customers in the region," said Roni Al-Dor, Sapiens CEO and President. "Our focus on speed to market for a quick product launch perfectly fit the needs of the bank."

07:35 EDT Beyond Air and Getz Healthcare partner to market LungFit PH in Asia-Pacific - Beyond Air has entered into an agreement with Getz Healthcare to commercialize the LungFit PH device in certain countries across the Asia-Pacific region, pending regulatory approvals. Under the terms of the agreement, Getz Healthcare will make a milestone payment to Beyond Air following CE mark certification of LungFit PH in the European Union. CE mark certification in Europe provides a pathway to approval in certain countries across the Asia-Pacific region. In addition, Beyond Air will receive ongoing royalty payments based on net sales of LungFit PH. The partnership provides access to hospitals in Australia, New Zealand, Thailand, Philippines, Taiwan, Hong Kong, Malaysia, Pakistan, Singapore and Vietnam. Getz Healthcare will manage the logistics, sales, service, and maintenance process in each of these countries where they have extensive experience with medical device distribution and hospital sales.

07:34 EDT Janover appoints Bruce Rosenbloom as CFO - Janover appointed Bruce Rosenbloom as CFO, effective September 07. Rosenbloom assumes the responsibilities formerly held by Patrick Stinus, Senior VP and Interim CFO, who resigned from his position with the company effective September 6. Rosenbloom most recently served as the CFO and Treasurer of PetMed Express. Prior to that, Rosenbloom was also a senior audit accountant for Deloitte & Touche, where he was responsible for planning and conducting all aspects of audit engagements for clients in various industries.

07:32 EDT Summit Materials, Cementos Argos combine in transaction valued at $3.2B - Cementos Argos announced it has entered into a definitive agreement with Summit Materials under which the U.S. operations of Cementos Argos, Argos North America Corp, will combine with Summit in a cash and stock transaction valued at $3.2B. Cementos Argos will achieve a strategic objective of acquiring a substantial equity stake in a New York Stock Exchange listed company through its 31% ownership stake in Summit. This combination unlocks estimated annual synergies of approximately $100 million per year, derived from optimized sourcing, enhanced operational efficiency, increased utilization of the import terminals' network, and an augmented asset base to increase the use of alternative fuels. The transaction is subject to antitrust regulatory approval, approval of Summit's shareholders, and other customary closing conditions. Both Summit and Argos North America will continue to operate independently until the necessary legal and regulatory approvals are met.

07:26 EDT Alnylam KARDIA-1 zilebesiran study met primary endpoint for hypertension - Alnylam Pharmaceuticals announced that the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen AGT in development for the treatment of hypertension, met the primary endpoint demonstrating a dose-dependent, clinically significant reduction in 24-hour mean systolic blood pressure measured by ambulatory blood pressure monitoring at Month 3, achieving a placebo-subtracted reduction greater than 15 mmHg with both 300 mg and 600 mg doses. The study also met key secondary endpoints including significant change in 24-hour mean SBP as measured by ABPM at Month 6, as well as significant change in office SBP at Month 3 and Month 6, for all zilebesiran arms, compared to placebo. The study results indicate zilebesiran was associated with dose-dependent, potent and durable knockdown of serum AGT levels through Month 6. Zilebesiran also demonstrated an encouraging safety and tolerability profile that the company believes supports continued development. These findings of robust and tonic blood pressure control will help determine the optimal dose and regimen of zilebesiran for future studies. "As a physician, I believe these KARDIA-1 results, which demonstrate clinically significant reductions in systolic blood pressure of greater than 15 mmHg, along with the ability to achieve durable tonic blood pressure control, provide hope that we may one day have access to a novel therapy with the potential to address the significant unmet needs of patients with uncontrolled hypertension who are at high risk of future cardiovascular events." Zilebesiran demonstrated an encouraging safety and tolerability profile. The primary endpoint is the change from baseline in SBP at Month 3, assessed by 24-hour ABPM. Key secondary and exploratory endpoints in this study include additional measures of blood pressure reduction at six months, time-adjusted change in blood pressure, and change in daytime average and night-time average blood pressure. "We are thrilled that the KARDIA-1 Phase 2 results show zilebesiran's ability to achieve sustained blood pressure reductions of greater than 15 mmHg, as well as long-term efficacy out to six months with infrequent dosing. We believe these results further validate the differentiated profile we observed in Phase 1. Moreover, they reinforce the potential for zilebesiran to be a transformative therapy to reduce cardiovascular risk in patients with hypertension and to offer new possibilities in a field of medicine that has seen limited innovation in nearly 20 years," said Simon Fox, Ph.D., Vice President, Zilebesiran Program Lead at Alnylam. " The KARDIA-2 Phase 2 study of zilebesiran used in combination with one of three standard classes of anti-hypertensive medications completed enrollment in June 2023. Topline results are expected in early 2024.

07:25 EDT Signal Gold initiates drilling at Dolliver Mountain Gold Mine - Signal Gold has initiated drilling at the past-producing Dolliver Mountain Gold Mine to the west of the Goldboro Mineral Resource based on encouraging results of a 14-line kilometre Induced Polarization geophysical survey at the Goldboro Project in Nova Scotia. The IP Survey, part of a broader 50-line kilometre IP Survey started in 2022, demonstrates that the chargeability response coincident with the Goldboro Deposit continues westward for at least 1.4 kilometres through the past producing Dolliver Mountain Gold Min. This is especially encouraging as the discovery of gold mineralization up to 325 metres to the west of the Goldboro Deposit announced in February 2023, which includes intercepts of 20.59 g/t Gold over 3.0 metres and 7.29 g/t Gold over 2.5 metres, demonstrated that increased gold mineralization and alteration is coincident with the targeted IP chargeability and Very Low Frequency trends. Based on these geophysical results, drilling has started at the past-producing Dolliver Mountain Gold Mine which was historically mining the same anticlinal structures as the Goldboro Deposit. "Signal Gold is excited to commence drilling to the west of the Goldboro Deposit by the historic Dolliver Mountain Gold Mine as part of our ongoing 12,000 metre diamond drill program, the Company's largest ever growth exploration program. The initial phase of the geophysical survey and recent drill results confirmed that the structure, alteration, and gold mineralization associated with the Goldboro Deposit continues to the west and the most recent results demonstrate that the chargeability response associated with the Goldboro Deposit continues through the past producing Dolliver Mountain Gold Mine. The best location to find a gold deposit is next to an existing deposit or in the shadow of a head frame - this opportunity meets those criteria and is associated with a clear and encouraging IP Survey. Armed with this knowledge, we have initiated drill testing in the Dolliver Mountain area with the aim of further demonstrating the significant opportunity to expand the near surface mineral resources at Goldboro and continue to demonstrate the scale potential of the emerging Goldboro Gold Camp." Kevin Bullock, President and CEO, Signal Gold Inc.

07:23 EDT Axsome Therapeutics to present data from central nervous system therapies - Axsome Therapeutics announced presentations of data from its CNS portfolio at the 2023 U.S. Psych Congress in Nashville September 6-10. The presentations will include eight posters with data and analyses which examine the effects of Auvelity on sleep quality and cognitive and physical functioning in patients with major depressive disorder, and the effects of Sunosi on cognition in patients with excessive daytime sleepiness due to obstructive sleep apnea. Five of the eight posters are finalists under consideration for the Psych Congress Poster Awards. Key highlights include: data examining durability of efficacy and tolerability with long-term - up to 12 months - treatment with Auvelity in patients with MDD, including measures of depressive symptoms, anxiety, and cognitive and physical functioning; data examining the effect of Auvelity on depression-related disability, and patient-reported measures of insomnia in patients with MDD; data examining treatment effect sizes of Sunosi in patients with EDS associated with narcolepsy and OSA; data examining the effects of Sunosi on cognition in patients with EDS and OSA.

07:21 EDT Hanesbrands G-III Apparel in licensing pact for Champion & C9 outerwear - HanesBrands (HBI) and G-III Apparel Group (GII) announced they have entered into a strategic multi-year license agreement for the design, production and distribution of outerwear for the Champion and C9 Champion brands in North America, including exploring opportunities across Champion's global network as a key partner. "We are thrilled to work with G-III's team of world-class experts in expanding and elevating iconic brands, making them a powerful partner as we grow Champion globally," said Vanessa LeFebvre, President, Global Activewear. "G-III's proven track record in category expansion and their best-in-class global infrastructure will enable us to reach a wider consumer base who already are, or will soon become, loyal to the Champion brand for generations. Champion is an inspirational lifestyle brand born from sport with a vision to be defined not by what we make, but by what we do. This partnership creates a significant opportunity to leverage G-III's expertise in the outerwear category and their diversified distribution network, which will enable us to extend our offerings and support the brand's lifestyle proposition."

07:20 EDT Alector completes enrollment in Phase 2 trial of Alzheimer's candidate AL002 - Alector (ALEC) has completed enrollment in INVOKE-2, the Phase 2 clinical trial of AL002. INVOKE-2 is evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease. Data from the trial are expected in Q4 2024. AL002 is being developed in collaboration with AbbVie (ABBV). INVOKE-2 is a randomized, double-blind, placebo-controlled, dose-ranging, multi-center Phase 2 clinical trial being conducted at multiple sites across 11 countries.

07:17 EDT Nayax's OTI PetroSmart partners with ai Corp. for smart fuel payment - Nayax's subsidiary OTI PetroSmart, a provider of integrated, end-to-end fuel management and payment solutions, has partnered with ai Corporation to provide its fleet card issuing and fuel payments platform aiEazyFuel to manage payment devices, including fraud management and provide transaction processing and repricing services for commercial fleet customers. aiEazyFuel will be integrated with OTI PetroSmart's Automated Vehicle Identification solution, EasyFuel Plus.

07:15 EDT CymaBay announces Phase 3 RESPONSE study achieved primary endpoint - CymaBay Therapeutics announced positive topline results from its Phase 3 pivotal RESPONSE study. The study evaluated the safety and efficacy of seladelpar, a potent, selective, orally active delpar or PPARdelta agonist, in development for the treatment of adult patients with primary biliary cholangitis. The registration trial achieved the primary and all key secondary endpoints and supports advancement to regulatory discussions and filing for regulatory approval with the U.S. Food and Drug Administration, the Medicines and Healthcare products Regulatory Agency, and the European Medicines Agency. A total of 61.7% of patients on seladelpar 10 mg met the primary composite endpoint related to serum alkaline phosphatase and bilirubin at 12 months versus 20.0% on placebo. The anti-cholestatic effect of seladelpar was supported by the normalization of alkaline phosphatase at 12 months in 25.0% of patients on seladelpar vs. zero on placebo. The least-squares mean percent reduction in alkaline phosphatase at 12 months was 42.4% in the seladelpar group vs. 4.3% in the placebo group. Seladelpar treatment compared to placebo also demonstrated a statistically significant reduction in pruritus, or itch, after 6 months of treatment. Seladelpar-treated patients with a baseline Numerical Rating Scale greater than or equal to 4 had a least-square mean reduction of 3.2 points in pruritus NRS compared to 1.7 points for patients in the placebo group. Overall, safety was comparable between placebo and seladelpar groups and was consistent with previous studies. Treatment-emergent adverse events, serious adverse events, and patient discontinuations were generally balanced across the treatment and placebo arms. There were no treatment-related serious adverse events in the study. Seladelpar's tolerability profile appeared favorable and consistent with previous studies.

07:13 EDT Avantor partners with Tobin Scientific to provide end-to-end solution - Avantor has entered into an agreement with Tobin Scientific to support end-to-end moves for biopharma customers looking to relocate their labs, research facilities, and samples. This partnership will deliver upon the growing customer need for complex logistics solutions with temperature-specific requirements. Avantor's collaboration with Tobin Scientific offers one primary partner to support critical moves, reducing downtime and offering flexibility for temporary or long-term storage. This solution removes the burden from the customer to solve their storage needs and provides current Good Manufacturing Practice compliance for temperature-controlled materials. "We are thrilled to be partnering with Avantor to help our customers, whether they are at the earliest stage of research or are among the largest biopharma players," said Brian Tobin, CEO of Tobin Scientific. "Our state-of-the-art storage and transport solutions, together with Avantor's diverse market reach, combine to provide essential services for all our customers."

07:11 EDT Durect announces last patient's last visit in Phase 2b AHFIRM trial - DURECT Corporation announced that the last patient has completed the study protocol in the Company's AHFIRM trial. AHFIRM is a Phase 2b randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of lasucosterol in subjects with severe alcohol-associated hepatitis. A total of 301 patients were randomized and dosed in AHFIRM and DURECT plans to report topline data in the fourth quarter of 2023. "We are pleased to have completed follow-up of all patients in our Phase 2b AHFIRM trial, bringing us one step closer to reporting topline data from the study which we anticipate in the fourth quarter of 2023," stated James E. Brown, D.V.M., President and CEO of DURECT. "Assuming a positive outcome from AHFIRM, we plan to review the results with the U.S. Food and Drug Administration (FDA) in the first quarter of 2024. We designed AHFIRM to be a potentially pivotal trial and hope to expedite regulatory discussions through the Fast Track Designation that the FDA previously granted. If approved, larsucosterol would be the first FDA-approved treatment for alcohol-associated hepatitis (AH) and would represent a paradigm shift in the management of this life-threatening disease."

07:10 EDT White Gold announces parital resuls from Betty Ford drilling - White Gold announces partial results from 2023 exploration diamond drilling at the Betty Ford target on the Betty property including 3.38 g/t Au over 53.0 m from 7.30 m depth in hole BETFD23D013, which included higher grade subintervals of 7.19 g/t Au over 6.30 m and 8.00 g/t Au over 4.35 m. Results of diamond drilling at the Vertigo target on the JP Ross property include 1.4 g/t Au over 58.4 m in hole JPRVER23D0052 from 40.95 m depth, and JPRVER23D0051 which intersected three zones of high-grade gold mineralization. Betty Ford and Vertigo are located approximately 65 km southeast and 30 km northeast respectively from the Company's flagship White Gold Project in west-central Yukon, Canada, which comprises 16 million tonnes averaging 2.23 g/t Au for 1,152,900 ounces of gold in the Indicated Resource category and 19 million tonnes averaging 1.54 g/t Au for 942,400 ounces of gold in the Inferred Resource category. The Betty property lies along strike and approximately 40 km east-southeast of Newmont Corporation's Coffee gold deposit with Indicated Resources of 2.14 Moz gold and Inferred Resources of 0.23 Moz gold. The Betty property is also contiguous to and 15 km northeast of Western Copper and Gold Corporation's Casino porphyry project with Measured & Indicated Resources of 14.8 Moz gold & 7.6 Blbs copper and Inferred Resources of 6.3 Moz gold and 3.1 Blb copper. The JP Ross property is road accessible and located in a prolific placer camp with significant recorded placer gold production. These drill programs form part of the Company's 2023 fully funded exploration program on its extensive and underexplored 350,000 hectare land package in the emerging White Gold District, Yukon, supported by strategic partners Agnico Eagle Mines and Kinross Gold. "We are pleased to encounter near surface high-grade gold mineralization over such a broad zone at Betty Ford which remains open for expansion. Furthermore, we have also encountered the first occurrence of gold within the deeper sulphide domain of the polylithic breccia unit while testing for possible feeder structures, which represents an important development in our understanding of Betty Ford and the potential to even further extend mineralization. The diamond drilling at Vertigo has improved our structural interpretation of the known mineralization controls at this high-grade gold target. These results continue to demonstrate the expansiveness of gold mineralization in our underexplored district scale exploration portfolio in a tier 1 mining district," stated David D'Onofrio, Chief Executive Officer.

07:09 EDT Alarm.com's SDS is granted two new patents by USPTO - Shooter Detection Systems, SDS, an Alarm.com company, announces the United States Patent and Trademark Office, USPTO, has granted two additional patents to its portfolio of indoor gunshot detection technologies, Patent No. US 11,604,248 and Patent No. US 11,688,414. Patent US 11,688,414 is the first SDS patent co-authored by Principal Hardware Designer Frank Bachmann. By utilizing stored energy more efficiently, sensors can consistently deliver exceptional reliability and reduced maintenance costs, creating better value for customers. The '248 patent, which is SDS's eighth patent, pertains to a novel testing mechanism supporting the sensor's practical testing utilizing the low-power approach, while SDS's ninth patent, the '414 patent, introduces methods and technologies for reducing sensor power consumption.

07:07 EDT Tilray launches new Redecan products across Canada - Tilray Brands announced the expansion of its market leading product portfolio with the launch of new flower genetics by best-selling cannabis lifestyle brand, Redecan. Redecan introduces a limited-edition series of exclusive whole flower cannabis genetics including; King Sherb and Animal RNTZ, two high-quality Indica strains meticulously cultivated by master growers. These new cannabis strains join the brand's award-winning product portfolio, including consumer favorites like Wappa, Cold Creek Kush and Glueberry OG.

07:05 EDT Secureworks reports Q2 EPS (10c), consensus (15c) - Reports Q2 revenue $92.966M, consensus $91.33M. "We expanded our Partner First ecosystem this quarter with global, market-leading partners, increasing our scale and market reach to further position our business for growth," said Wendy Thomas, CEO, Secureworks. "As an open XDR platform that combines security analytics, AI, threat intelligence and automation, Taegis is empowering organizations to say goodbye to point solution chaos and embrace a platform-based approach that results in better security outcomes, optimized resources and the highest return on investment for our customers and partners."

07:04 EDT Entrada Therapeutics awards funding to non-profit organizations - Entrada Therapeutics announced recipients of its inaugural Entrada Diversity, Representation, Equity and Advocacy MatterS Grant Program. Entrada DREAMS grant recipients - The Akari Foundation, Neurology and Neuromuscular Care Center and Parent Project Muscular Dystrophy - will each be awarded $25,000 to support initiatives that aim to better identify, understand and reach those within the Duchenne community who are currently underrepresented or underserved.

07:03 EDT Canada Nickel publishes first ESG report - Canada Nickel Company announce the publication of its 2022 Environmental, Social, and Governance, ESG, Report. Mark Selby, CEO of Canada Nickel said, "Publicizing our initial ESG Report is a significant step in our commitment to transparency and accountability with Indigenous Nations, stakeholders, investors, employees, key business partners, and regulators. We recognize that meeting the demand for critical minerals can only be successfully achieved if we also meet our responsibilities to communities and the environment. Canada Nickel is fully committed to applying a sustainable mindset to strategic decision-making while maintaining our focus on positive outcomes, meaningful collaboration, and continuous improvement."

06:58 EDT Asensus Surgical, Nvidia collaborate on augmented intelligence capabilities - Asensus Surgical announced a collaboration with NVIDIA to accelerate the development of Asensus's Intelligent Surgical Unit and improve its ability to deliver novel clinical intelligence to surgeons. Asensus will utilize a broad suite of NVIDIA tools to enhance the augmented intelligence capabilities of its ISU. Asensus's ISU is built with NVIDIA accelerated computing technology and has been bringing real-time augmented intelligent features - such as digital tags, 3D measurement, and enhanced camera control - to surgeons since 2021. As part of the collaboration, both companies will have early access to relevant product roadmaps, fostering synergistic development. Furthermore, Asensus and NVIDIA plan to jointly define innovative business models for the development, deployment, and commercialization of digital surgical solutions.

06:56 EDT Laser Photonics launches DefenseTech MLRI-2000 - Laser Photonics recently launched its DefenseTech MLRI-2000 as part of its military-focused product line. The DefenseTech MLRI-2000 is designed to remove rust, coatings and contaminants from a variety of surface types and materials. Laser Photonics' DefenseTech cleaning equipment provides a safe and effective solution to maintaining vehicles, aircraft, ships, equipment and more. All products in the DefenseTech line are specifically designed to meet military standards and are housed in military-grade cases.

06:38 EDT Xiao-I showcases AI solutions for e-commerce industry - Xiao-I took center stage at the 2023 Shanghai Livestream E-commerce Industry Expo, showcasing its leadership by presenting AI solutions tailored for the livestream e-commerce sector. The company said, "The Xiao-I Robotic Process Automation E-commerce Robot was a star of the Expo which is a valuable asset for businesses engaged in livestream e-commerce. Leveraging Xiao-I's expertise in Natural Language Processing, AI, and General Computing, this robot offers 24/7 responsiveness, versatile cross-system capabilities, traceable processes, high precision, cost-effectiveness, and the ability to replace error-prone human tasks. Its multifaceted capabilities span web interactions, data extraction, and system inputs, providing crucial business insights that catalyze e-commerce operational transformation, driving efficiency, and streamlining processes."

06:35 EDT Fisker Ocean to ramp up production to 300 units per day in Q4 - Fisker is ramping up production capacity of the Fisker Ocean all-electric SUV in September, as well as expanding retail, delivery, and service operations across multiple markets in North America and Europe. The expected ramp will go from approximately 180 vehicles per day to approximately 300 per day in Q4 2023, with Fisker working with suppliers to achieve this run rate in October. Production is for customer deliveries in all European markets: Austria, Belgium, Denmark, France, Germany, the Netherlands, Norway, Sweden, Switzerland, the United Kingdom; and for Canada and the U.S. East and West Coasts, as well as other states. As of earlier in the week of Sept. 4, 3,123 customer vehicles have been manufactured by production partner Magna Steyr, with just under 3,000 handed over to Fisker. In the US, over 450 Fisker Oceans have been either delivered to customers or are in the process of being delivered. More than 1,500 additional vehicles are arriving by ship in the US, beginning this weekend. Europe has received nearly 1,000 vehicles and 325 have been delivered. Fisker anticipates receiving all 5,000 Fisker Ocean One launch edition vehicles from Magna by September 30, 2023, and although the company's goal remains to deliver as many of these vehicles as possible by the end of September, deliveries may stretch into October.

06:20 EDT Patterson-UTI reports average of 117 drilling rigs in U.S. operation in August - PATTERSON-UTI ENERGY reported that for the month of August 2023, the Company had an average of 117 drilling rigs operating in the United States. For the two months ended August 31, 2023, the Company had an average of 120 drilling rigs operating in the United States.

06:17 EDT Kodiak Sciences announces topline results from tarcocimab tedromer study - Kodiak Sciences announced top-line, one-year results for its ABC Platform based investigational therapy tarcocimab tedromer 5 mg from the pivotal BEACON study in patients with macular edema due to retinal vein occlusion, or RVO. In the initial six months of the study, patients received Kodiak's tarcocimab tedromer 5 mg on a fixed every 8-week dosing regimen following only 2 monthly loading doses or aflibercept 2 mg on a fixed monthly dosing regimen per its label. In the second six months of the study, tarcocimab and aflibercept were tested head-to-head according to a pro re nata protocol in which patients in both groups were treated only when disease reactivated according to matched predefined disease activity criteria. Tarcocimab showed matched efficacy with differentiated durability versus aflibercept in the head-to-head comparison. After 4 initiating doses in the first 6 months, 47% of tarcocimab-treated patients required no additional injections in the second 6 months. Despite receiving 6 initiating monthly doses, only 37% of aflibercept patients were injection free in the second half of the study. 77% of tarcocimab treated patients received 5 or fewer doses in year one, while 93% of aflibercept treated patients received 6 or more doses. BRVO patients received a median of 4.0 injections on tarcocimab versus 7.0 injections of aflibercept. Despite materially fewer injections in tarcocimab treated patients, vision outcomes favored tarcocimab-treated patients achieving an observed mean of 76.6 letters versus 75.6 letters for aflibercept treated patients. All RVO patients received a median of 5.0 injections on tarcocimab versus 7.0 injections of aflibercept. Despite materially fewer injections in tarcocimab treated patients, vision outcomes favored tarcocimab-treated patients achieving an observed mean of 74.6 letters versus 74.3 letters for aflibercept treated patients. Safety and tolerability were comparable between tarcocimab and aflibercept. Intraocular inflammation rate was comparable between groups. No cases of inflammation associated with vascular occlusion or vasculitis were reported. The overall number of cataracts was low in the full year follow-up, comparable to prior aflibercept RVO studies and comparable between groups.

06:14 EDT SciSparc granted 180-day extension by Nasdaq to regain compliance - SciSparc has been granted by Nasdaq that it has been granted an additional 180-day compliance period, or until March 4, 2024 to regain compliance with Nasdaq's minimum bid price rule. Nasdaq's determination is based on the company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on Nasdaq, with the exception of the bid price requirement, and the company's written notice of its intention to cure the deficiency during the second compliance period and if necessary, by effecting a reverse stock split. If at any time before March 4, 2024, the closing bid price of the company's ordinary shares is at least $1.00 per share for a minimum of 10 consecutive business days, the company will regain compliance with this Nasdaq rule and this matter will be closed. This current notification from Nasdaq has no immediate effect on the listing or trading of the Company's ordinary shares, which will continue to trade on Nasdaq under the symbol "SPRC."

06:12 EDT Beam Global reports no EV ARC Systems disabled by Hurricane Idalia - Beam Global announced that none of its EV ARC products were disabled by Hurricane Idalia. EV ARC systems in Florida, Georgia and the Carolinas which were in the direct path of the hurricane continued to provide EV charging and emergency power throughout the storm, when several locations where EV ARC systems are deployed experienced prolonged grid outages as a result of the hurricane. The storm made landfall on Florida's Gulf Coast cutting off power to more than 470,000 customers in Florida and Georgia. Beam Global customers in the impacted region include the U.S. Army, the U.S. Marine Corps, the U.S. Department of Veterans Affairs, and the Department of Homeland Security. ARC systems are independently rated to withstand winds of 160 mph and are able to continue to operate in 9.5 feet of flooding. They can be equipped with an optional Emergency Power Panel which provides 120v and 240v outlets for use by first responders or other authorized users when utility power is not available.

06:12 EDT Tower Semiconductor, InnoLight partner to develop optical transceivers - Tower Semiconductor and InnoLight Technology announced their collaboration to develop multi-generation high-speed optical transceivers based on Tower's Silicon Photonics process platform. With production already underway, this strategic partnership is expected to enable cutting-edge solutions to support the growing demands of AI, datacenters, and next-generation telecom networks.

06:10 EDT Liberty Gold reports drill results from Black Pine Oxide Gold Project - Liberty Gold reports the latest assay results from an additional 8 holes drilled in the Rangefront Zone with most holes focused on the eastern margin of the known deposit area. These results are part of the 2023 Reverse Circulation drill exploration program at its Black Pine Oxide Gold Project in southeastern Idaho. RANGEFRONT ZONE HIGHLIGHTS: 0.61 grams per tonne gold over 76.2 meters, including 2.47 g/t Au over 12.2 m in hole LBP941. 0.45 g/t Au over 73.2 m, including 1.50 g/t Au over 3.0 m in hole LBP954. Drill results from 8 additional RC drill holes completed in the Rangefront Zone have been received with results showing the known mineralization continues to the east and becomes thicker with better grades than blocks in the current resource model. These holes were drilled on the eastern margin of the resource area and were planned to test for extensions to the modeled mineralization and to convert inferred resource blocks to indicated resource blocks as the area had only been sparsely tested with shallow historic drilling. This drilling shows a large area of oxide mineralization, that is predominantly outside of the current pit constrained resource and is still open for expansion to the north and south. This area is roughly 200 m x 200 m in plan view and extends from near surface to a depth of about 200 meters. The area to the east is unconstrained by any drilling and the area to the south has only been tested by shallow historic drilling. This new drilling pushes the known extents of mineralization at the Rangefront Zone to an area roughly 1000 m x 1000 m with room to grow the deposit to the east, north and south.

06:07 EDT Biodesix presents on lung cancer guidance tests at IASLC 2023 - Biodesix announced that two abstracts will be presented at the International Association for the Study of Lung Cancer (IASLC) 2023 World Lung Conference on Lung Cancer. The first presentation showcases a new analysis of the large multi-center observational registry study INSIGHT demonstrating the ability of the VeriStrat host immune classifier to predict response to immune checkpoint inhibitor regimens in patients with advanced stage non-small cell lung cancer. The INSIGHT trial, which recently reached its enrollment goal of 5,000 patients with NSCLC, previously yielded data showing that patients with greater than or equal to50% PD-L1 status classified as Host Immune Classifier Cold, also known as VeriStrat Poor, had superior median overall survival when receiving ICI plus chemotherapy versus ICI alone. The expanded analysis confirms these findings and concludes that patients with less than50% PD-L1 status classified as Host Immune Classifier Hot, also known as VeriStrat Good, had comparable overall survival when receiving either ICI alone or in combination with chemotherapy. The second presentation details the performance of a pre-surgical, blood-based Risk of Recurrence test in three independent cohorts. Patients with early stage lung cancer have favorable outcomes, but many of these patients experience a recurrence which results in a poor prognosis. The test was designed to identify patients with a high probability of recurrence that could be considered for more aggressive treatment or enhanced surveillance. This initial validation study evaluated nearly 800 patients with Stage I NSCLC and demonstrated the test's ability to stratify three distinct groups of patients based on their proteomic profile with high, intermediate, or low risk of recurrence. Furthermore, incorporating the adenocarcinoma grade, a conventional risk factor for recurrence, improved the performance of the test.

06:03 EDT KKR to invest $750M to scale Zenobe - KKR is investing approximately $750M to scale Zenobe, a market leader in transport electrification and battery storage solutions, to accelerate the global decarbonisation of diesel fleets and provide grid services that are critical for the decarbonisation of the energy sector. Infracapital, will invest further alongside KKR and the management team, with KKR and Infracapital becoming joint majority shareholders. The transaction is subject to customary closing conditions and regulatory approvals. KKR's investment in Zenobe is the first to be made through the firm's global climate strategy, which is part of KKR's $54B global Infrastructure business and dedicated to investing in solutions at scale to support the transition to a low-carbon economy.The company said, "Founded in 2017 and headquartered in London, Zenobe is a global player in electrification solutions for fleets and battery storage solutions for grid network infrastructure, with leading positions in the UK, Australia and New Zealand, and a growing presence in continental Europe. Today, Zenobe is one of the leading fleet electrification platforms in the world, helping bus and increasingly HGV operating companies to decarbonise their fleets and meet emission-reduction objectives. Zenobe's EV fleet business provides end-to-end solutions to transition conventional internal combustion engine vehicles to electric, including financing of chassis, batteries on the vehicles, and charging infrastructure in depots, complemented with an integrated software solution. Through its network infrastructure business, Zenobe develops and builds large scale batteries that connect to transmission grids, providing essential grid services to complement the growth of intermittent low carbon energy generation and allowing economies to achieve their net zero ambitions, without compromising the grid stability. Decarbonising transportation, reducing pollution in big cities and towns and meeting national net-zero targets will require substantial investment and a rapid shift to electric vehicles. The transport sector is the largest source of carbon emissions globally, resulting in tightening regulations related to emissions by public transport. KKR plans to work with Zenobe to meet the growing demand for EV adoption from bus operators and other commercial fleet businesses globally. KKR also expects to help Zenobe expand its grid-scale battery storage capacity through the construction and expansion of new and existing sites. The investment will help Zenobe to build on its leadership positions in the UK, Australia and New Zealand, while continuing to grow across continental Europe, and also expand into North America."

05:17 EDT Fluor to sell Stork business in Belgium, Germany and the Netherlands - Fluor announced that it has agreed to sell its Stork business in Belgium, Germany, the Netherlands and its turbo blading manufacturing operation in the United States to industrial services provider Bilfinger SE. This divestiture advances Fluor's strategic initiative to focus on its core businesses and capital priorities. This transaction is subject to consultations with and advice from the representative body of the applicable works councils, consultations with the trade unions and receipt of regulatory clearances along with other customary conditions and, subject to these conditions, is expected to be completed in the first half of 2024.